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Obesity is associated with a host of co-morbidities including hyperglycemia, insulin resistance, 
Type II diabetes (T2D), and cognitive deficit.  The present study examined the modulation of 
weight, blood metabolites, bio-behaviors, and neuro-immune function by a high fat diet.  
C57BL/6J male mice were fed a 60% fat diet (high fat diet; HFD) or a 10% fat (low fat diet; 
LFD) for 1 or 3 weeks post-weaning, after which mice were subjected to behavioral testing.  
HFD-fed mice had increased anxietal-like and reward seeking behavior and decreased 
performance in spatial and non-spatial memory tasks compared to mice fed a LFD.  There was 
no difference in spontaneous locomotion or depressive-like behavior between diet groups. 
Additionally, non-spatial memory deficit was restored in mice fed HFD for 1 week by feeding a 
LFD for 1 week. Interestingly, IL-1R1 -/- mice displayed non-spatial memory deficit regardless 
of diet, implicating a role for IL-1 in HFD- induced memory deficit. Analysis of the mRNA 
expression of key cytokines and growth factors in the hippocampus, hypothalamus, and cortex 
did not show differences in the expression of IL-1 or IL-1 receptors after 1 week of diet feeding, 
but showed reduced expression of two key growth factors related to memory, brain-derived 
neurotrophic factor (BDNF) and nerve growth factor (NGF), in HFD-fed mice compared to 
LFD-fed mice. Finally, memory impairment in HFD-fed mice was corrected with administration 
of methylphendidate, a stimulant that increases the synaptic concentration of dopamine and 
norepinephrine by blocking dopamine transporters.  Anti-depressants, desipramine and 
reboxetine, both norepinephrine re-uptake inhibitors, did not correct memory deficit in HFD-fed 
mice. Dietary fiber (DF) is associated with a reduction in the risk of obesity and T2D.  The 
present study also examined the protective effect of soluble and insoluble fibers on weight gain 
and T2D.   C57BL/6J male mice were fed a HFD or LFD supplemented with pectin, cellulose, 
resistant starch, or fructooligosaccharide for 10-12 weeks.   Mice fed a HFD + 10% pectin were 
protected against weight gain, while mice fed a HFD + 5% pectin, 5% pectin and 5% cellulose, 
10% resistant starch, or 10% fructooligosaccharides were not.   Supplementation of a HFD with 
10% pectin also slowed HFD-induced elevation of fasting blood glucose and significantly 
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decreased blood glucose concentrations when presented with an intraperitoneal glucose 
challenge.   Supplementation of a HFD with 10% pectin slowed weight gain in IL1R1-/-, IL4-/-, 
and MyD88-/- mice, but not in TLR4-/- or TLR2-/- mice.  Finally, fecal lipid excretion was 
significantly increased in pectin-supplemented animals compared to cellulose, suggesting that 
pectin’s ability to form viscous gels results in decreased lipid digestion and absorption, 
contributing to the differences noted in weight gain between diet groups. This research 
demonstrates that HFD-feeding has an immediate, detrimental effect on bio-behaviors in juvenile 
mice.  In addition, this research demonstrates that HFD-induced weight gain and hyperglycemia 
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The prevalence of juvenile obesity has more than tripled in the last 30 years (1). 
Especially concerning is the accompanying rise in previously “adult-only” co-morbidities such 
as hypertension, hyperglycemia, insulin resistance, Type II diabetes, cardiovascular disease, and 
stroke (1-3). Furthermore, increasing epidemiological evidence suggests an association between 
obesity and reduced cognitive function and psychiatric disorders such as attention deficit 
hyperactivity disorder (ADHD) and dementia (4-7). The prevalence of ADHD has been found to 
be higher in obese cohorts compared to non-obese controls (8, 9). Additionally, obesity and 
ADHD share similar pathophysiology, such as anxiety, inattention, and executive function deficit 
(10, 11). There is some debate as to whether inflammation associated with obesity leads to 
cognitive dysfunction noted in ADHD or if increased impulsivity and poor decision making 
ability lead to obesity (8). A third possibility is that both ADHD and obesity share the same 
mechanism involving the dopaminergic pathway (11, 12). As the consumption of fast food and 
convenience food increased globally, the global prevalence of juvenile obesity has increased 
exponentially. Understanding the effects of short-term exposure to a high fat diet (HFD) on bio-
behaviors such as spontaneous movement, learning, and anxietal/depressive-like behaviors in 
juveniles is crucial, as these are critical in early brain development.    
 
The current study focused on the immediate effect of a HFD on modulation of bio-
behaviors related to both obesity and ADHD: anxiety, depression, locomotion, and cognition.  In 
addition, this study further explored the proposed common mechanism between these conditions 
by examining HFD-induced changes in cytokines and growth factors purported to alter the 
dopaminergic pathway.  
 
Dietary fiber (DF) has been associated with risk reduction of obesity and several related 
co-morbidities such as type II diabetes (T2D) and cardiovascular disease (13-16). The health 
benefits of DF are dependent on the type of DF and the physical characteristics of the fiber. 
Benefit is conferred in part by altering gastrointestinal transit, slowing gastric emptying, and by 
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delaying or inhibiting the absorption of macronutrients. Degree of solubility, fermentability, and 
gel-forming ability varies by DF.  This is reflected in the inconsistent results of clinical trials 
exploring the ability of DF to reduce weight (14, 17-20)  and hyperglycemia (21, 22). 
Understanding the attributes of each fiber is critical in developing dietary interventions.  This 
study also explored DF supplementation of a HFD. Here, DF of varying solubility and 
fermentability were used to determine extent of protection against weight gain.   Additionally, 
pectin was used to further explore the mechanism by which soluble fiber reduces the risk of 
diabesity (obesity + T2D). 
 
This study contributes novel and critical research to understanding the role of a HFD on 
the co-morbid conditions of obesity and ADHD.  It also provides additional insight into the 
beneficial effects of DF on prevention of obesity and T2D. 
 
1.2 Specific Aims 
 
Specific Aim 1: 
Determine the immediate effect of a HFD on bio-behaviors and neuro-immune function in a 
juvenile mouse model. 
 
We hypothesized that HFD feeding would increase anxiety, depression, and memory deficit in 
mice after 3 weeks of feeding.  Additionally, we hypothesized that HFD feeding would result in 
disregulation of pro-inflammatory cytokines and growth factors related to neuronal plasticity, 
specifically in the hippocampus and cortex, areas of the brain that are related to memory and 
learning. 
 
Specific Aim 2:  
Determine the effect of dietary fiber supplementation of HFD on weight modulation and blood 
metabolites related to type II diabetes. 
 
We hypothesize that soluble fibers (pectin, fructooligosaccarides, and resistant starch) would 
result in less weight gain over a 12 week period than the insoluble fiber, cellulose.  In addition, 
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we predicted that pectin would reduce hyperglycemia in HFD-fed animals compared to 
cellulose-fed animals. 
 
Secondary Aim 2: 
Determine if the ability of pectin to prevent weight gain is solely due to the capacity of pectin to 
form viscous gels. 
 
We hypothesized that pectin-fed animals would have increased fecal lipid excretion compared to 
cellulose-fed animals.  We also hypothesized that knockout animals deficient in TLR4, TLR2, 
and MyD88 would not be protected from HFD-induced weight gain by pectin supplementation 
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The health benefits of dietary fiber: Is there anything beyond the discussion of diabesity, 
cardiovascular disease, and colon cancer? 
 
2.1 Introduction 
Dietary fiber (DF) decreases the risk of type 2 diabetes (T2D), cardiovascular disease, 
and colon cancer (1-4) by reducing the digestion and absorption of macronutrients and by 
decreasing contact time of carcinogens with the intestinal lumen (1, 2, 5, 6). In addition, health 
claims supporting the role of DF in the prevention of cancer and coronary heart disease (CHD) 
have been approved by the Food and Drug Administration in the United States (7, 8). More 
recently, and perhaps more interestingly, epidemiological studies have found the benefits of DF 
to extend beyond T2D, CHD, and colon cancer. A 9 year follow-up study of 567,169 American 
Association of Retired Persons (AARP) members aged 50-71 years old found that in addition to 
reducing the risk of all-causes of mortality, intake of DF was inversely related to mortality from 
respiratory and infectious diseases (9). In a cross-sectional study of 1538 pregnant women, 
higher DF intake was associated with reduced risk of preeclampsia (10). DF also may increase 
positive mood, cognition, and alertness (11, 12). The mechanisms by which DF specifically 
exerts all its protective effects remain to be elucidated, but its ability to physically disrupt macro- 
and micronutrient absorption has been extensively explored. More recently, the role of DFs in 
positively impacting human health through alteration of the intestinal microbiome has gained 
significant traction (13, 14). DF-dependent changes in gut bacterial composition are thought to 
modify host metabolism in a variety of ways ranging from the enhancement of bile acid 
deconjugation (15, 16), production of short chain fatty acids (SCFAs) (17), to modulation of 
inflammatory bioactives. Here we define DF and provide an overview of the impact of DF on 
metabolism and the microbiome. We also discuss the impact of DF on conditions and diseases 
not directly linked to diabesity, CHD, and colon cancer.    
 
2.2 Defining Dietary Fiber 
DF is a broad category of non-digestible food ingredients that include non-starch 
polysaccharides, oligosaccharides, lignin, and analogous polysaccharides that have an associated 
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health benefit (3, 6). The physical properties of DFs vary and even a slight variance may 
influence the physiological effect of the DF. Generally, DFs are classified by solubility in water, 
microbial fermentation in the large intestine, and viscosity. Soluble DFs include pectin, gums, 
and polysaccharides, while insoluble DFs include cellulose, hemicelluloses, and lignin (3).  
Previously, it was erroneously believed that soluble DFs decreased serum lipids and cholesterol 
while insoluble DFs solely contributed to fecal bulking. Current thought attributes the 
physiologic effects of a particular DF to its degree of viscosity and fermentation (18). In 
addition, the definition of what comprises a DF has been expanded to include resistant starches 
and oligosaccharides that have properties similar to soluble DFs (19). Prebiotic DFs are not 
classified in terms of solubility or viscosity but are defined by resistance to digestion and 
absorption in the small intestine, partial or complete fermentation by microbiota in the large 
intestine, and by the ability to stimulate growth of select bacteria (17).  Only two such DFs fit all 
of the above three criteria and are considered prebiotics: inulin and trans-
galactooligosaccharides. In the near future, polydextrose and several other oligosaccharides may 
be classified as prebiotics due to their ability to meet the above conditions (20).  
 
The human microbiome is dominated by Bacteroides and Firmicutes (21). Fermentable 
DFs shift gut microbial populations by providing substrates for select bacteria to ferment. 
Fructooligosaccharides and galactooligosaccharides increase fecal bifidobacteria and 
lactobacillus populations in infants (22, 23), while inulin increases populations of bifidobacteria 
in adults (24). DFs can be partially or completely fermented to the SCFAs acetate, propionate, 
and butyrate (25) (Table 1). Fermentation patterns and the ratio of SCFAs produced are 
dependent on DF type. Acetate is the main product of pectin fermentation (26), while 
fermentation of gum arabic and dextrins results primarily in propionate (27, 28). Okara increased 
cecal butyrate and decreased cecal acetate concentrations in female rats fed 10% okara for 4 
weeks compared to standard rodent chow (29). Acetate and propionate enter the liver via portal 
circulation where they are almost fully metabolized (30). Butyrate, on the other hand, is 
metabolized by β-oxidation in colonic enterocytes (31). Finally, the physiologic effects of DFs 
are due, in part, to type and amount of SCFAs produced and the ability of these SCFAs to 
stimulate intestinal water and sodium absorption as well as influence gut pH and bile salt 




Given the linkage between elevated body mass index (BMI), T2D, and CHD (2, 19), the 
role of DF in weight reduction has been examined in animal and human studies. A strong inverse 
relationship between DF intake and weight has been established in animal models (28, 29, 33-36) 
and by epidemiological studies (37-40). A prospective cohort study of 74,091 females spanning 
12 years found women in the highest quintile for whole grain consumption had a 49% lower risk 
of major weight gain than women in the lowest quintile. Interestingly, the effect of DF on 
prevention of weight gain was most significant in individuals who were overweight at baseline 
(39). A prospective cohort study of 894,332 European individuals followed for 6.5 years found 
total DF intake associated with weight and waist circumference (37). In this study, cereal DF was 
associated with weight while DF from fruit and vegetables was not. Unfortunately, research 
tying increased DF intake to weight loss is inconsistent in human clinical trials (3). Overall, 
conflicting results in humans may be due to DF type, dosage, and study population. A meta-
analysis consisting of 14 random control trials, examining glucomannan and weight loss, found 
that glucomannan supplementation significantly reduced weight (41). In a randomized placebo 
controlled study of 167 overweight individuals, supplementation of 1240 mg/day of 
glucomannan in addition to a calorie-restricted diet resulted in greater weight loss after 5 weeks 
than a calorie-restricted diet alone (42). In a parallel double blinded placebo-controlled clinical 
trial, weight loss tended to be greater, but not significantly so, in obese individuals receiving 
supplements of 3 grams Plantago ovarto (psyllium) + 1 gram glucomannan 2 or 3 times per day 
in addition to a calorie-restricted diet for 16 weeks compared to placebo (43). While 
glucomannan seemed to show promise in the reduction of weight, not all clinical trials have 
demonstrated a weight loss effect. Supplementation of 10 grams of guar gum (glucomannan) 3 
times per day for 6 weeks did not result in a weight difference compared to the control period in 
a double blind placebo-controlled cross-over trial of 25 non-obese men. Overall, diet 
supplementation with DF appears to be more effective for weight reduction in overweight or 
obese populations and when used in combination with a calorie-restricted diet. Clinical 
interventions with other DFs also have produced inconsistent results regarding weight (3). As an 
example, chitosan, a DF popular in over–the-counter weight loss treatments, reduced weight in a 
random double blind placebo-controlled clinical trial of 230 overweight or obese persons 
receiving 3 grams chitosan or a placebo daily for 24 weeks (44). While the weight loss in this 
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study was significant between the DF and placebo groups (0.4% loss in the chitosan group 
compared to a 0.2% gain in the placebo group), the reduction in weight was not clinically 
relevant. In sum, a diet high in a variety of soluble and insoluble DFs from whole grains, cereals, 
fruits, and vegetables may be more effective in weight regulation than supplementation with a 
single DF.   
 
Reduction in T2D risk by DFs also appears to be dependent on type and dose of DF and 
study population. In animals, soluble DFs decrease T2D related bio-markers. In mice, 10% 
psyllium and 10% sugar cane fiber decreased fasting blood glucose and fasting plasma insulin 
when added to a high fat diet for 12 weeks when compared to the insoluble fiber, cellulose (45). 
β-glucan also improved glucose tolerance and decreased serum insulin in mice when added to a 
high fat diet at a 2 and 4% level (34). In contrast, diabetic dogs fed an insoluble DF had lower 
maximum and mean blood glucose concentrations and a lower area under the blood glucose 
curve compared to dogs fed a soluble DF or a low DF diet (46). In humans, muffins high in β-
glucan and resistant starch lowered postprandial blood glucose and insulin more effectively than 
muffins containing low or medium β-glucan/resistant starch (5). Plantago ovarta husk 
supplementation of 14 grams per day for 8 weeks, however, reduced serum insulin but not 
plasma glucose compared to placebo (47). Surprisingly, despite the ability of soluble DFs to 
reduce diabetes-associated biomarkers, soluble DFs have not been associated with a reduced risk 
of T2D in population-based studies (48). In a large prospective cohort study of 99,826 women, 
intake of total DF, total insoluble DF, and DF from cereal was inversely related to risk of 
diabetes. There was no association found between intake of soluble DF and diabetes risk (48). 
This again highlights the difference in effectiveness between DFs as part of a balanced diet and 
DFs as stand-alone supplements. 
 
The protective effect of DF on obesity and T2D has historically been attributed to greater 
satiety resulting from increased mastication, calorie displacement, and decreased absorption of 
macronutrients (49). The mechanism is believed to be due to the ability of soluble DFs to form 
viscous solutions that prolong gastric emptying, thus inhibiting the transport of glucose, 
triglycerides, and cholesterol across the intestinal wall (6, 46, 50-52).  As an example guar gum 
was shown to reduce in vitro glucose absorption by reducing simulated intestinal contractions 
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(53). Viscous DFs form gels that decrease luminal content contact with pancreatic lipases and 
bile by forming DF-lipid aggregates that block fat emulsification and micelle formation (51). 
Increased viscosity of luminal contents also thickens the unstirred water layer, thereby 
decreasing diffusion and uptake of cholesterol and glucose from the intestinal lumen (54). 
Certain DFs can, in turn, bind bile acids and micelle components such as monoglycerides, free 
fatty acids, and cholesterol that decrease absorption and increase fecal excretion of these entities 
(55-57).   
 
DFs also modify lipid (Table 2) and carbohydrate (Table 3) metabolism by influencing 
the expression of key genes and hormones. Acetyl-CoA carboxylase is the rate limiting enzyme 
in lipogenesis and is regulated by AMP-activated protein kinase. In a 10 week study comparing 
obese and lean rats, 5 grams of Plantago ovarto, when added to rat chow, increased the 
phosphorylation of AMP-activated protein kinase, thus inhibiting acetyl-CoA carboxylase. This 
inhibition of acetyl-CoA carboxylase in obese rats was comparable to the acetyl-CoA 
carboxylase activity in lean rats fed a control diet (58). Fructoligosaccharide (10 grams/ 100 
grams) also has been shown to decrease hepatic acetyl-CoA carboxylase expression in rats (59). 
Increases in SCFAs due to bacterial fermentation may activate hepatic AMP-activated protein 
kinase (60). Synthesis of fatty acids, primarily palmitate, is catalyzed by the fatty acid synthase 
complex. Reductions in fatty acid synthase expression have been demonstrated in rodents fed 
resistant starch, fructans, inulin, β-glucan, Plantago ovarto, and hydroxylpropylmethycellulose 
(34, 35, 58, 59). Alteration in gene expression may be due to DF-induced modulation of gut 
microbiota and subsequent SCFA production. Conventionalization of germ free mice resulted in 
increased hepatic triglycerides with a corresponding increase in mRNA expression of hepatic 
acetyl CoA carboxylase-1 and fatty acid synthase (61). Butyrate activates colonic fatty acid 
synthesis by contributing carbon atoms for de novo lipogenesis (62, 63). Finally, 
supplementation of 1.0% gum arabic in the drinking water of female mice over 180 days resulted 
in increased expression of triacylglycerol lipase and hormone sensitive lipase in paranephric fat, 
enzymes involved in mobilizing fatty acids from adipocytes (28, 64). Gum arabic also increased 
expression of fasting-induced adipose factor, a lipoprotein lipase inhibitor that blocks the 
incorporation of fatty acids into low density lipoprotein (28). This increase in fasting-induced 
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adipose factor may be the result of modulation of the intestinal microbiome as fasting-induced 
adipose factor is synthesized in the intestinal epithelium in response to microbiota (61). 
 
The rate-limiting enzyme of cholesterol synthesis, HMG-CoA reductase, converts HMG-
CoA to mevalonate. While β-glucan supplementation in mice did not alter hepatic expression of 
HMG-CoA reductase, hydroxylpropylmethycellulose was shown to increase hepatic expression 
in hamsters (34, 35). A combination of inulin and oligofructose, however, increased hepatic 
expression of HMG-CoA reductase in rats (65). Increased HMG-CoA reductase may be due to a 
depletion of cholesterol pools resulting from increased excretion of bile cholesterol. Catabolism 
by microbial populations also may be important. Bacteria such as L. acidophilus and 
bifidobacteria can exert a hypocholesterolemic effect by enhancing bile acid deconjugation (15, 
16). Furthermore, lactobacilli and bifidobacteria remove cholesterol in vitro by assimilation and 
precipitation (25, 66). Fermentation products further affect lipid metabolism. Propionate inhibits 
the incorporation of acetic acid into fats and sterols, resulting in decreased fatty acid and 
cholesterol synthesis. Demigne  et al. demonstrated, in rats, that propionate inhibited fatty acid 
and cholesterol synthesis by blocking the integration of C1,4 into fatty acids (62). 
 
 Carbohydrate metabolism also is influenced by DF intake. Insoluble DFs appear to 
improve insulin sensitivity, but the mechanisms by which insoluble DFs impact insulin signaling 
is unclear (6, 67). Both soluble and insoluble DFs may be involved in the regulation of hormones 
such as glucose-dependent insulin tropic polypeptide and glucagon-like peptide-1 that stimulate 
postprandial insulin release, enhance glucose tolerance, and delay gastric emptying (2, 68). In a 
study of 14 women, control meals of insoluble DF increased insulin responsiveness as well as 
glucose-dependent insulin tropic peptide (67). Proglucagon, a precursor of glucagon-like peptide 
1, is produced in the L-cells of the distal ileum and colon and is increased by butyrate production 
(69). A diet high in fermentable DFs , as opposed to cellulose, increased expression of 
proglucagon mRNA in the ileum of dogs and rats and the colon of dogs (36, 69). An increase in 
postprandial plasma glucagon-like peptide-1 was noted as well (6, 69). DFs may increase 





 Shifts in the gut microbial population affect the manifestation of diabesity. As noted 
above, the human microbiome is comprised primarily of bifidobacteia and firmacutes (21). 
Obesity in both mice and humans is linked to an increase in firmacutes and a decrease in 
bifidobacteria (21). This microbial misbalance is corrected by weight loss in humans. The 
obesity-associated microbiome has a heightened capacity for energy harvest (70), which may 
attenuate weight gain. Certain DFs, such as inulin and oligofructose, increase bifidobacteria 
populations and may prevent a shift towards an obesity-associated microbiome (71, 72). As 
evidence, antibiotic-induced changes in gut microbial populations of obese mice resulted in 
improved glucose tolerance (73), indicating that the obese state microbiome also may influence 
diabetes related characteristics. 
 
2.4 Inflammation 
Chronic inflammation is inherent to a variety of diseases, including diabesity. DFs appear 
to be anti-inflammatory, decreasing inflammation-associated biomarkers and bioactives 
including C-reactive protein (CRP), IL-6, and TNF-α (58, 74, 75). In a case-control study of 88 
individuals that examined the relationship of DF intake to plasma cytokine and chemokine 
concentrations, no association was found between the intake of total, soluble, or insoluble DF to 
any cytokine or chemokine examined. However, intake of cereal DF was associated with a 
reduction in an inflammatory bioactive array that was comprised of IL-1 , IL-6, TNF-α, IL-4, 
IL-5, and IL-13 (76). This immune profile suggests anti-inflammation seen with the macrophage 
deactivation (IL-10) phenotype. Conversely, in a cross-sectional study of 1953 overweight post-
menopausal women, intake of total, soluble, and insoluble DFs were all inversely associated with 
plasma IL-6 and TNF-α concentrations (75). Several epidemiologic studies have demonstrated 
an inverse relationship between DF intake and CRP, a sensitive marker of inflammation, and 
CHD (74, 77, 78). In an examination of NHANES data containing 14,533 adults, intake of total, 
insoluble, and soluble DFs were linked to lower serum CRP. In addition, a subgroup of persons 
with chronic kidney disease who reported higher DF intake had decreased mortality from all 
causes (78). While most epidemiologic studies demonstrate an association between DF intake 
and anti-inflammatory properties, cohort and cross-sectional study designs make it difficult to 
ascertain if DF supplementation would be successful in reducing inflammation. To this end, 
intervention trials have reported inconsistent results which, as mentioned earlier, may reflect 
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fiber type, dose, and study population. In a prospective randomized controlled trial of 158 
overweight or obese persons receiving 7 or 14 grams per day of psyllium, there was no 
difference in serum CRP or IL-6 concentrations compared to the control group (79). Distinctly, 
in a pre-test/post-test study involving 19 elderly nursing home patients, 4 grams of 
fructooligosaccharides delivered 2 times per day for 3 weeks caused a decrease in granulocyte 
and monocyte phagocytic activity and lower blood IL-6. This study additionally demonstrated 
increased fecal bifidobacteria (72). Supplementation of fructooligosaccharides in infant formula, 
however, appears to afford long-lasting protection against allergens and infection. 
Galactooligosaccharides and fructooligosaccharides added to the formula of 134 infants for 6 
months resulted in a lower incidence of atopic dermatitis, wheezing, upper respiratory tract 
infections, and fever in the 2 years following intervention (80). Lending support to the relevance 
of galactooligosaccharides to infection prevention is a study in 427 college students given 2.5 or 
5 grams of galactooligosaccharide daily. Over the 8 week study period when compared to control 
subjects, stress-induced gastrointestinal symptoms were decreased as were the percentage of 
days of cold and flu (81). Given that fructooligosaccharides and galactooligosaccharides increase 
fecal bifidobacteria and lactobacilli (22, 23, 72), the immunomodulation seen in the above 
human studies may be the result of DF-induced changes in gut microbial populations.  
   
With fermentable DFs, gut-generated SCFAs may be responsible for the modulation of 
appetite, insulin signaling, and inflammation. In adipose tissue, propionate down-regulated the 
pro-inflammatory cytokine TNF-α (82). In vitro, SCFAs suppressed release of TNF-α from LPS-
stimulated human neutrophils while also reducing IL-6 mRNA and protein in cultures of human 
colonocytes (83). SCFAs appear to communicate with the immune system through G-protein-
coupled free fatty acid receptors. Free fatty acid receptor 3 (FFA3) is expressed primarily by 
adipocytes and is activated by propionate, butyrate, and acetate. Activation of adipocyte FFA3 
by propionate leads to elevated leptin secretion, while activation by butyrate sparks adipogenesis 
(84). FFA2 expression is noted in leukocytes and colonic L-cells in addition to adipocytes. FFA2 
is activated primarily by propionate (84) and to a lesser extent by acetate (85). Like FFA3, FFA2 
may regulate differentiation of adipocytes but it also appears to lessen fat cell triglyceride storage 
capacity and accumulation of body fat deposits (86). How this relates to the ability of FFA2 to 
decrease plasma free fatty acids (84) and increase adipocyte insulin sensitivity is unclear (86). 
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Interestingly, DFs may increase cellular expression of FFA2 as 5% nopal (a DF containing a 
40:60 ratio of soluble to insoluble fiber) increased colonic FFA2 by 31%  in rats (87). Bypassing 
FFA2, DFs may interact directly with immunoregulatory cells. Mucosal macrophages and 
dendritic cells have pattern recognition receptors with carbohydrate binding domains that are 
able to bind certain DFs, such as β-glucans, causing decreased IL-12 and increased IL-10 (88) 
which is consistent with an anti-inflammatory phenotype. Overall, the mechanism by which 
fermentable DFs work may not be principally related to their ability to act as a SCFA source.  
 
 
2.5 Cognition and Memory 
 Inflammation is an important component of many neurodegenerative diseases. 
Alzheimer’s disease and vascular dementia are both associated with increased CRP, IL-6, and 
TNF-α (89). CRP is neurotoxic and neuron-synthesized CRP can initiate neuro-apoptosis (89). 
The progression of Alzheimer’s disease has been linked to both oxidative stress and AB-induced 
neurotoxicity. An extract of Triticum aestivium L., a type of wheat crop, was shown to protect 
cells from AB cytotoxicity and apoptosis in vitro. Additionally, Triticum aestivium L. reversed 
scopolamine-induced spatial memory deficits in rats (90). While research in this area is limited, 
DF intake may affect cognition and mood due to the role of systemic inflammation in depressive 
and anxietal disorders (89). A 1.5 g fiber breakfast bar increased positive mood and performance 
on a free recall task (12). DF also has been shown to ameliorate pre-depression-associated 
sickness behaviors in mice because diets containing 10% pectin reduced endotoxin-dependent 
social withdrawal and fever compared to diets containing 10% cellulose (91). Furthermore, in a 
community-based study of 394 post-menopausal women, ingestion of lignan improved cognitive 
performance (11). Mechanistically, microbiota-dependent production of SCFAs is likely key to 
DF-induced memory and behavioral changes because administration of SCFAs ellicit alterations 
in brain functions. Butyrate, possibly via histone hyperacetylation, increased brain-derived 
neurotrophic factor, a bioactive critical to neuronal plasticity (92). Administration of propionate 
to rats induced autism-like behavioral changes (92), while diet-induced alterations in gut 
microbiota generated detrimental effects on mouse cognition and behavior (93). Finally, 
dysregulation within the hypothalamic-pituitary-adrenal (HPA) axis results in depression and 
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anxiety (92)  and commensal bacteria have been shown to influence the HPA axis and reduce 
behavioral abnormalities (92).   
 
2.6 Conclusion 
 The definition and chemical characterizations of DFs are well documented and 
understood as is the ability of DFs to reduce absorption of macronutrients by increasing viscosity 
of luminal contents and altering intestinal transit time. The impact of DFs on lipid metabolism is 
clearly delineated, especially in terms of enhancing expression of key enzymes of β-oxidation 
and de novo lipogenesis, namely triacylglycerol lipase, hormone-sensitive lipase, acetyl-CoA 
carboxylase, and fatty acid synthetase. DFs are hypocholesterolemic, modulating expression of 
HMGCoA reductase, decreasing cholesterol synthesis, and increasing excretion of cholesterol in 
bile. The process by which DFs improve glycemic control and insulin sensitivity are less clear. 
Soluble DFs may lower blood glucose by slowing carbohydrate absorption in the gut via 
increased viscosity. Epidemiological studies, however, fail to find a solid relationship between 
soluble DF intake and reduced risk of T2D. Finally, emerging research suggests that DFs may 
influence immunity by altering plasma concentrations of key bioactives such as CRP and TNF-α, 
through modulation of gut microbiota. Such immune system modifications likely tied to SCFA 
and FFA2 suggest a link to the brain-cytokine system as evidenced by the ability of certain DFs 
to regulate sickness symptoms and cognitive function. While these exciting new functions for 
DFs are intriguing, much work needs to be done to determine the mechanism by which DFs exert 








Table 1.  Summary of the effects of dietary fiber on cecal short-chain fatty acid concentrations and lipid excretion. 
Fiber Species Propionate Acetate Butyrate Total SCFA Fecal Lipid Fecal Bile References 
α-Cyclodextrin  rodent     +  13 
β-Cyclodextrin rodent + + - +   49 
Cassia tora 
Linn. 
rodent     + + 53 
Hydroxylpropyl- 
methylcellulose 
rodent      + 16 
Gum arabic rodent + - - -   29 
Okara rodent + +  +- +  15 
Pectin rodent + + + +   41,67 
Passion fruit rodent     + + 36 
Resistant 
starch 
rodent     +  38 
“+”indicates dietary fiber affects this property positively or negatively.  “-“indicates dietary fiber did not have an effect on this property. 
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Table 2.  Summary of the effects of fiber on biomarkers related to dyslipidemia and hypercholesterolemia 
















          
α-Cyclodextrin  rodent  -  +/-  -  13 
β-Cyclodextrin rodent +   +  +  49 
β-glucan 
(barley) 
rodent   +/- +/-  +/-  14,40 
 human    -  +  6 
Blueberry peel 
extract 
rodent - -  - - + + 59 
Cassia tora 
Linn. 
rodent   + +  +  53 
Hydroxylpropyl-
methylcellulose 
rodent + +  + +/- + + 16,92 
 human      +  9 
Gum arabic rodent   + -  +  29 
Glucomannan 
(guar gum) 
human    +  +  23 
Inulin 
(oligofructose) 
rodent +   + + +/- + 35,88 
 human   - +  -  10 
Okara rodent  +  +/- +/- +/- +/- 15,51 
Passion fruit rodent    +  +  36 
PolyGlycopleX 
(PGX) 
rodent    +    17 
Psyllium rodent   + + + +  55,87 
 human    +  +  1,8,52 
Resistant 
starch 
rodent +   - + + + 38 





Table 3.  Summary of the effects fiber on weight and biomarkers related to Type II diabetes 
Fiber Species Weight Plasma 
Glucose 
GTT Plasma Insulin ITT References 
α-Cyclodextrin  rodent + -  -  13 
β-Cyclodextrin rodent -     49 
β-glucan or barley rodent +/- +/- + +/-  14 
  human  - + - + 6 
Blueberry peel extract rodent -     59 




+/- +/-  - 
 
16,92 




- +  + 
 
23 
Inulin (oligofructose) rodent - +  +  35 
  human   -  -  10 
Okara rodent - -    15,51 
Pectin rodent +/-       41,67 
 human -     46 
Passion fruit rodent -       36 
PolyGlycopleX (PGX) rodent + -  -  17 
Psyllium rodent +/- +/-  +  12, 55, 90 
  human - +/- - +/-  1, 7, 52 
Resistant starch rodent -      38 
“+” indicates dietary fiber affects this property positively or negatively.  “-“ indicates dietary fiber did not have an effect on this 
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The modulation of bio-behaviors by a short-course high fat diet in juvenile mice 
 
3.1 Introduction 
In 1997, the World Health Organization (WHO) declared the global increase in obesity 
one of pandemic proportions (1). The prevalence of juvenile obesity alone has more than tripled 
in the last 30 years (2). The Center for Disease Control (CDC) defines obesity in adolescents as 
at or over the 95
th
 percentile of sex-specific body mass index (BMI) for age growth charts and 
overweight as over the 85
th
 and under the 95
th
 percentile (3).  An NHANES study found 31.5% 
of children overweight and 16.0% of children obese in 2000-2001. In addition, 11.4% of infants 
and 10% of 2 to 5 year olds were found to be overweight (4). Especially concerning is the 
accompanying rise in previously “adult-only” co-morbidities such as hypertension, 
hyperglycemia, insulin resistance, Type II diabetes, cardiovascular disease, and stroke (2, 4, 5). 
Furthermore, increasing epidemiological evidence suggests an association between obesity and 
reduced cognitive function and psychiatric disorders such as attention deficit hyperactivity 
disorder (ADHD) and dementia in both children and adults (6-12). Several epidemiological 
studies have found a negative association between obesity or overweight and decreased 
performance on tests of executive function (impulsivity, decision making, and problem solving) 
and attention (13). In addition, the prevalence of ADHD is greater in obese and overweight 
cohorts compared to controls (14, 15). Altered dopaminergic function has been implicated in 
both disorders, alluding to the possibility of a shared mechanism (16). 
In humans, a critical stage in brain development, the brain growth spurt, begins in the 
third trimester of pregnancy and continues to approximately age 3 (17, 18). The brain growth 
spurt period is associated with a rapid increase in brain weight, proliferation of astroglial or 
oligodendroglial cells, neuronal axonal elongation and dendritic abromization and 
synaptogenesis (19).  The developing brain is especially vulnerable to insult by environmental 
factors such as diet (17, 20, 21). The juvenile mouse is an appropriate model for studying the 
effects of a high fat diet on the developing brain as a similar brain growth spurt period occurs in 
mice within the first few weeks following birth.   In addition, a host of behavioral characteristics 
can be measured in the mouse such as spontaneous locomotion, anxietal- and depressive-like 
behavior, and cognition. Several studies have reported that a high fat diet impairs learning 
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acquisition and both non-spatial and spatial memory in adult rodents (22-26).  While a high fat 
diet seems to have an effect on learning and memory in older rodents fed a high diet fat for an 
extended period of time, little exploration has been made into the immediate effect of a high fat 
diet on the juvenile mouse. In one of the few studies investigating short-term high fat diet 
feeding effects, cognition was negatively affected in 2 mo old rats following 9 d of feeding a 
55% fat diet (27). Here we placed 3 wk old mice on a 60% fat (HFD) or a 10%  fat (LFD) diet 
and performed behavioral tests beginning after 1 wk of feeding to determine the immediate 
effects of a HFD on bio-behaviors, learning, and neuro-immune function in juvenile mice. We 
further used knockout mouse models and pharmaceutical intervention to explore mechanism. To 
our knowledge, this is the first study that has investigated the immediate effect of a HFD on bio-
behavior in juvenile mice. 
 
3.2 Methods 
Animals- C57BL/6J male mice (3 wk old) were purchased from Jackson Laboratories (Bar 
Harbor, ME).   IL1R1 -/-, IDO -/-, and TLR4 -/- male mice were bred in house and weaned at 3 
wk old.  Mice were group housed (4-8 per cage) in large standard shoebox cages (length 28 cm; 
width 17 cm; height 12.5 cm) and allowed free access to food and water.  Housing temperature 
(72°F) and humidity (45-55%) were controlled, as was a 12/12 h reversed dark-light cycle (2200-
1000 h).  Video recording of animal behavior was performed under red light using a night shot 
capable video camera (Sony HDR-XR500V) except in the zero maze test where mice were 
recorded in white light to induce anxiety. Animal use was conducted in accordance with 
Institutional Animal Care and Use Committee (IACUC) approved protocols at the University of 
Illinois, Urbana. 
 
Diets, weight, and fasting blood glucose - Mice were fed open source uniform-base diets 
containing either 10% calories from fat (LFD) (D12450B, Research Diets, New Brunswick, NJ) 
or 60% calories from fat (HFD) (D12492, Research Diets, New Brunswick, NJ). Both diets 
contained 20% kcal from protein (casein). The LFD contained 70% kcal from carbohydrates 
(corn starch) and 10% calories from fat (soybean oil and lard).  The HFD contained 20% kcal 
from carbohydrates (corn starch) and 60% calories from fat (soybean oil and lard).  Mice had 
free access to food and water for study duration (1 to 3 wk).  Mouse weight was recorded weekly 
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using an Adventurer Pro digital scale (Ohaus, Parsippany, NJ).  Mice were fasted for 12 hrs prior 
to tail blood collection. Fasted mice were provided water ad libitum.  Mouse tail blood glucose 
was recorded weekly using a FreeStyle Freedom blood glucose monitor (Abbott, Abbott Park, 
IL) after the tail was cleaned with 70% ethanol and lanced with a sterile No. 10 surgical scalpel 
blade (Feather, Osaka, Japan). 
  
Quantitative PCR (qPCR)-  Mice were sacrificed after 1 or 3 wk of feeding by CO2 asphyxiation.  
Brains were perfused with 1% phosphate buffered saline (PBS) to eliminate contaminating 
blood, and brain sections (hippocampus, cortex, and hypothalamus) were collected in 1 mL 
Trizol (Invitrogen, Carlsbad, CA) and stored on ice until homogenization with the Tissuelyser  
II(Qiagen, Hilden, Germany).   Homogenate then was stored at -80 
0
C until RNA extraction was 
performed.   RNA isolation from brain sections was performed using a lipid tissue mRNA 
extraction kit (Qiagen, Hilden, Germany). RNA was reverse transcribed using the High-Capacity 
cDNA Reverse Transcription Kit (PN 4368813) (Applied Biosystems, Carlsbad, CA). The 
TaqMan Gene Expression primers used were: F4/80 (Mm00802529_m1), IL-1α 
(Mm99999060_m1), IL-1β (Mm99999061_mH), IL1R1 (Mm00434237_m1), IL1R2 
(Mm00439622_m1), IL1RA (Mm01337566_m1), IL-6 (Mm01210733_m1), CD11b 
(Mm00434455_m1), tumor necrosis factor- α ( TNF-α) (Mm00443258_m1), CD45 
(Mm00448490_m1),  tyrosine hydroxylase (TH) (Mm00447554_m1), cyclic AMP responsive 
element binding protein-1 (CREB1) (Mm00501607_m1), brain derived neurotrophic factor 
(BDNF) (MM01334042_m1), ARG/ARC (Mm01190441_g1), and nerve growth factor 
(NGF) (Mm00443039_m1).  qPCR was performed on a 7900 HT Fast Real-Time PCR System 
(Applied Biosystems, Carlsbad, CA) using TaqMan Universal PCR Master Mix (Applied 
Biosystems, Carlsbad, CA). To compare gene expression, a parallel amplification of endogenous 
Rps3 (Mm00656272_m1) was performed. Reactions with no reverse transcription and no 
template were included as negative controls. Relative quantitative evaluation of target gene to 
rps3 was performed by comparing ∆Cts, where Ct is the threshold concentration.  
 
Behavioral Tests: 
Spontaneous Alternation (Y-maze)- Spontaneous alternation is used to access locomotion and 
hippocampal-dependent spatial memory. Alternation utilized a symmetrical 3-arm, clear 
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Plexiglas Y-maze (arms = 40 cm in length x 9 cm in width x 16 cm wall in height with an arm 
angle of 120
o
). Maze bottom was blue and side walls were decorated with either black triangles, 
black circles, or black diagonal lines.  Mice were single housed in small standard shoe box cages 
overnight prior to testing. To initiate testing, the subject mouse was randomly placed in one of 
the 3 maze arms. Movement was recorded for 5 min and evaluated from the video record.  
Results are presented as total arm entries, perfect alternations, and imperfect alternations. Perfect 
alternations were defined as exploration of all three arms sequentially given 3 opportunities 
independent of a right or left arm choice at initiation.   Imperfect alternations were defined as 
entry into all three arms in 4 opportunities.  Score was calculated as the number of perfect or 
imperfect alternations divided by total opportunities. To have entered an arm the mouse was 
required to have all 4 legs in the arm.  
 
Novel Object Recognition Test-  The novel object recognition test (NOR) is a test of non-spatial 
cortex-dependent memory that exploits an animal’s propensity to explore a novel object more 
than a familiar object.  Mice were single housed in small standard shoe box cages with 2 
identical objects (familiar objects) per cage overnight prior to testing. For the acclimation period, 
mouse was placed in a large standard cage with light bedding (novel arena) containing the 
familiar objects.  Objects were placed 10 cm apart at the short-side wall end 5 cm from the short 
side wall and 6.5 cm from the long-side wall.   Mice were recorded for 5 min and then returned 
to home cages for 1 h.  For testing, mice were placed in the novel arena containing one familiar 
object (cleaned with 70% alcohol prior to reuse) and one novel object.  Objects used included a 
glass stone, a 6-sided plastic die, or a shaped constructed from small building blocks. 
Exploratory behavior was video-recorded for 5 min and evaluated from video record.  Object 
exploration was defined as the mouse touching the object with nose or paws.  Sitting on object 
was not considered exploration. Data are presented as percent exploration of the novel object.  
Percent investigation was calculated by dividing the time spent examining the novel object by 
the total time spent investigating both objects multiplied by 100.   
 
Locomotor Activity- The locomotor activity test is used to assess spontaneous movement. Mice 
were single housed overnight prior to testing.  For testing, nestlet was removed from home cage 
and cages were placed on the floor.  Mice were examined in their home cage by video recording 
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for 5 min.  Movement was quantified using EthoVision XT 7 (Noldus Information Technology, 
Leesburg, VA).  
 
Wheel running activity- Voluntary wheel running behavior is considered a self-rewarding 
activity as well as a measure of activity level.  Mice were single housed in standard cages 
containing a stainless steel running wheel (Mini-Mitter, Bend, OR) 2 h prior to start of dark 
cycle.  Wheel turn data were collected via a magnetic reed switch that sent the information to a 
computer with VitalView Software (Mini-Mitter, Bend, OR).  Data were collected for 1 h 
intervals and summed for 24 h wheel turns. Data are presented as total wheel turns for first 24 h 
period after either 1 wk or 3 wk of diet feeding. 
 
Burrowing- Burrowing is an innate behavior in mice used to test anxiety and reward seeking 
behavior.   Burrows were constructed of 20.3 cm long ASTM D2665 polyvinyl chloride (PVC) 
pipe fitted at one end with an ASTM D2665 PVC pipe cap (closed end). The open end was 
raised 1.3 cm on twin steel legs. To acclimatize mice to the burrow, mice were single housed in 
large standard cages with burrow present overnight prior to testing. Testing was initiated 2 h 
prior to the dark cycle by adding 100 g of food pellets to the burrow. Prior to replacing the 
burrow filled with food (burrow + food) back into the cage, the burrow + food was weighed. The 
burrow then was placed horizontal to the cage long-side wall with the closed end against the cage 
short-side wall. Water was provided ad libitum, but food was only available from the burrow. 
Mice were allowed to dig and or eat the food out of the burrow for 30 min. Burrows were then 
removed and weighed. Amount burrowed was calculated by subtracting the burrow + food 
weight before and after the 30 min period of burrowing.   
 
Swim test-   The forced swim test is used to measure depressive-like behavior in mice by 
assessing mobility. Decreased activity in the forced swim test is indicative of increased 
depressive-like behavior. Mice were single housed in standard cages overnight prior to testing.  
Testing was initiated by individually transferring mice from their home cage to a clean white 
cylindrical PVC container (diameter 16 cm; height 31 cm) containing 15 cm of water maintained 
at 25 ± 1
o
 C. Total swim duration was 6 min and immobility was evaluated from the video record 
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encompassing the final 5 min of the swim.  After testing, mice were patted dry with paper towels 
and dried under a heat lab and then returned to their home cage.  
 
Elevated Zero Maze- The elevated zero maze is used to measure anxiety-like behavior in mice by 
assessing the amount of time spent in an open area of an elevated platform.  The zero maze 
utilized a circular platform (6 cm width with a 40 cm inner diameter) elevated 72 cm from the 
ground.  The maze is equally divided into 4 quadrants, 2 of which are enclosed by walls (14 cm 
high) and two quadrants that are open and bordered by a lip 0.3 cm high.  To initiate testing, the 
mouse was placed in closed section of zero maze and video recorded in white light for 5 min.   
Video record was evaluated for percent time spent in open areas and number of head dips. 
Percent time was calculated as time spent in open area divided by total time multiplied by 100.  
A head dip was considered as mouse’s head extending beyond the maze lip in the open area. 
 
Pharmaceutical Intervention- To correct non-spatial memory deficit, stimulants or anti-
depressants were administered prior to the acclimation phase of novel object testing.  Mice were 
injected intraperitoneally with caffeine (25 mg/kg) (Bedford Labs, Bedford,OH),  reboxetine (1 
mg/kg) (Sigma Aldrich, St. Louis, MO), desipramine (1 mg/kg) (Sigma Aldrich, St. Louis, MO),  
or methylphendidate (2.5 mg/kg) (Medisca, Quebec, Canada) after overnight object acclimation, 
45 min prior to novel object acclimation phase. 
 
Statistical analysis- Data analysis was conducted using Sigma Plot 11.2 (Systat Software,  
Chicago, IL). Weight and behavioral data were subjected to 1-way analysis of variance 
(ANOVA) to determine the main effects of diet (LFD or HFD) followed by Tukey adjustment.  
When normality failed (P<0.05), the  Kruskal-Wallis 1-way analysis of variance was performed 
followed by a Tukey adjustment when group size was equal and a Dunn’s adjustment in cases 
where group size was not equal.  qPCR data were analyzed using unpaired t-tests to determine 
differences between diet groups. Statistical significance was assumed at P<0.05 and all data are 







HFD induces weight gain and elevation of fasting blood glucose 
HFD-fed mice gained significantly more weight than LFD-fed mice after 21 d of feeding. 
(22.26g±0.73 vs. 19.83g±0.58) and had significantly elevated fasting blood glucose 
concentrations after 14 d of feeding (148.38mg/dL±7.90 vs. 109.69mg/dL±11.62).  There was no 
difference in weight between diet groups after 7 (17.18g±0.61 vs. 18.64g±0.83) or 14 
(18.23g±0.61 vs. 20.15g±0.82) d of feeding, and no difference in fasting blood glucose levels 
after 7 d of feeding (105.63mg/dL±9.16 vs. 108.94mg/dL±5.42) (Figure 1A-B). 
 
HFD increases wheel running, but not spontaneous locomotor activity 
HFD-fed mice had increased wheel running activity (greater wheel turns/d) compared to mice 
fed a LFD after 7 d of feeding (2914.5±492.51 vs. 1242.75±283.16), while there was no 
significant difference in wheel running activity between diet groups after 21 d of feeding 
(4122.00±938.28 vs. 3679.38±1161.80) (Figure 2A). There was no difference in spontaneous 
locomotor activity (total distance traveled or velocity) between the HFD and LFD groups after 7 
or 21 d of feeding (Figure 2B,C). 
 
HFD increases anxietal- but not depressive-like behavior 
HFD-fed mice burrowed a significantly greater weight of food pellets than LFD-fed mice after 7 
d of feeding (45.61±9.04 vs. 14.91±7.15) and 21 d of feeding (87.19±6.35 vs. 46.83±11.12) 
(Figure 3A). In the forced swim test, HFD-fed mice were significantly less immobile after 21 d 
of feeding (243.113±19.85 vs. 212.82±14.8) while there was no difference in immobility 
between diet groups after 1 wk of feeding (239.93±28.43 vs. 271.81±23.24) (Figure 3B).  HFD- 
fed mice spent less time in the open area of the zero maze after 7 d of feeding (52.46±6.48 vs. 
36.91±2.90) while there was no difference in time spent in open area between diet groups after 
21 d of feeding (49.53±3.29 vs. 42.89±5.26) (Figure 3C) or in number of total head dips after 7 
or 21 d of feeding (data not shown).  
 
HFD impacts non-spatial and spatial memory 
In the novel object recognition test, a test of non-spatial memory, mice fed a HFD explored a 
novel object less than LFD-fed mice after 7 d of feeding (50.80±4.21 vs. 72.00±1.75) and 21 d of 
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feeding ( 54.76±3.55 vs. 81.5±22.09) (Figure 4A).  In the Y-maze, a test of spatial memory, 
HFD-fed mice had decreased perfect alternations compared to LFD-fed mice after 7 d of feeding 
(0.66±0.02 vs. 0.58±0.03), while there was no difference after 21 d of feeding (0.66±0.03 vs. 
0.61±0.03).  There also was no difference in total arm entries (7 d: 30.75±1.55 vs. 31.38±1.60; 
21 d: 126.06±0.03 vs. 26.44±0.99) or imperfect (7 d: 0.82±0.01 vs. 0.80±0.02; 21 d: 0.85±0.03 
vs. 0.83±0.02) alternations between HFD- and LFD-fed mice at 7 or 21 d on diet (data not 
shown). 
 
LFD feeding restores novel object recognition in HFD fed mice 
Novel object recognition was restored in mice fed a HFD for 7 d followed by LFD feeding for 7 d.  After 
7 d of feeding, HFD- and LFD-fed mice explored a novel object differentially (67.21 ±2.82 vs. 
51.50±3.56). HFD mice then were switched to a LFD.  After 7 d of additional feeding, mice were retested 
using a different novel object.  Both diet groups explored a novel object equivocally at retest, at greater 
than 70% exploration (78.78 ± 2.82 vs. 70.05 ±3.26) (Figure 5). 
HFD does not affect NOR in IL1RI -/- or IDO -/- mice 
IL1R1 -/- mice explored a novel object equivocally (approximately 50% of total exploration) 
regardless of diet or time on diet (7 d: 53.16±3.28 vs. 5.19±3.90; 21 d: 50.86±3.98 vs. 
56.33±4.26) (Figure 6A).  HFD-fed IDO-/- mice explored a novel object significantly less than 
LFD-fed IDO-/- mice (65.37±2.33 vs. 51.84±3.89) (Figure 6B).   
 
HFD impacts expression of brain cytokines and growth factors related to inflammation, memory, 
and learning 
Figure 7 (A-E) shows HFD-fed mice when compared to LFD-fed mice have differential mRNA 
expression of IL-6, BDNF, NFG, IL1R2, IL1R2, and IL1RA that is dependent on brain region 
and time.  IL1-α, IL1-β, F4/80, CD45, TNF-α, CD11b, ARG/ARC, TH, and CREB1 mRNA 
were expressed at similar levels irrespective of diet, time, or brain regions (data not shown). 
Methylphenidate administration corrects non-spatial memory deficit in HFD-fed mice, while 
anti-depressants and caffeine do not 
Administration of reboxetine and desipramine resulted in equivocal exploration of a novel object 
between drug injected LFD and HFD mice of approximately 50-55% of total exploration, 
indicating an inability to discriminate between novel and familiar objects (reboxetine: 
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56.48±5.39 vs. 51.34±5.39; desipramine: 56.95±5.79 vs. 47.69±2.22) (Figure 6A-B). 
Administration of methylphenidate resulted in equivocal exploration of a novel object between 
drug-injected LFD- and HFD-fed mice (60.03±1.86 vs. 66.11±5.32), equal to novel object 
exploration of vehicle-injected LFD-fed animals (Figure 6C).  Administration of caffeine 
resulted in differential exploration of the novel object by LFD- and HFD-fed drug-injected mice, 
although the difference did not reach significance (60.73±3.88 vs. 39.97±4.53).  
 
3.4 Discussion 
Epidemiological evidence indicates there is an association between obesity, depression, 
anxiety, and cognitive decline in both adults and adolescents (7, 28-30).  As the prevalence of 
obesity and associated co-morbidities rises within the juvenile population, an understanding of the 
mechanism by which a HFD affects these characteristics in juveniles becomes critical.  Here, we 
demonstrate that a HFD increases reward-seeking and anxietal-like behavior and induces memory 
deficit after 7 d of feeding post-weaning independent of significant change in body weight or 
elevation in fasting blood glucose.  Interestingly, increased anxiety, reward-seeking, and cognitive 
deficit also are seen in obese cohorts and in children and adults with attention deficit disorder 
(ADHD) (13, 14). 
 
 After 7 d of HFD feeding, juvenile mice burrowed 66% more compared to mice fed a 
LFD and continued to have increased burrowing (40% greater) after 21 d of feeding compared to 
LFD-fed mice.  Traditionally, changes in burrowing activity have been equated to anxiety-like 
behavior, as burrowing is utilized in nature to hide from predators and conceal food (31).  This 
may not be the case in a laboratory setting, as mice will burrow or kick out substrate from a 
container in a fashion similar to the “spring cleaning” behavior seen in wild field mice, even if an 
empty container is present (32). Thus, burrowing behavior may be interpreted as a reward 
behavior, a behavior that mice find pleasurable.  In fact, Sherwin et al. demonstrated mice are 
motivated to burrow and can be taught to press a level to access burrowing material, even when 
no immediate need to burrow is present (33). Further behavioral testing revealed both increased 




Voluntary wheel running activity also can be viewed as a reward behavior (34).  Here, 
HFD-fed mice had 48% greater wheel turns in the 24 h period following 7 d of diet feeding 
compared to LFD-fed mice.  This increase in activity seen in burrowing and wheel running cannot 
be attributed to an increase in general locomotor activity resulting from HFD consumption as 
there was no difference between diet groups in terms of spontaneous locomotor activity or total 
arm entries in the Y-maze. We previously demonstrated a 35% decrease in spontaneous 
locomotor activity in adult HFD-fed mice that were fed for 12 wk compared to LFD-fed mice 
(35).  This could have been due to a large significant weight difference and differences in fasting 
blood glucose between the two diet groups. Here, after 7 d of feeding, there was no significant 
difference between HFD- and LFD- fed mice in terms of weight or fasting blood glucose.  While 
spontaneous movement may be decreased in adult HFD-fed mice, several studies have 
demonstrated an initial increase in wheel running activity in adult HFD-fed mice compared to a 
control (34, 36).  In contrast, Ma et al. did not find a difference in wheel running activity between 
HFD-fed and control-fed mice, but mice were 7 wk old when placed on a HFD compared to 
previous studies that placed mice on study diets within 0-2 wk of weaning (37).  This suggests 
that a HFD may have an effect on brain development, as changes in reward-seeking activity are 
only seen when mice are placed on a HFD at weaning.   
 
In addition to an increase in reward-seeking and anxietal-like behavior, we found that a 
HFD has an immediate, detrimental effect on non-spatial and spatial memory.  Here we used the 
novel object recognition test (NOR) to assess non-spatial memory as it does not use an external 
reward and does not induce additional anxiety with water or food restriction.  The NOR tests a 
mouse’s ability to discriminate between a familiar and novel object.   HFD-fed mice explored a 
novel object 29% less often than LFD-fed mice after 7 d of feeding and 32% less after 21 d of 
feeding. Several studies have demonstrated impaired NOR in adult mice fed a 45% fat diet 
compared to a control diet (23, 24). In contrast, we previously found no difference in NOR in 
adult mice fed a 60% fat diet compared to mice fed a 10% fat diet (35).  This may be due to 
differences in diet composition or experimental design.  Acclimation to familiar objects in this 
study was longer than in previous studies. In this study, mice were acclimated to the familiar 
object overnight and we used larger, more complex objects.  HFD feeding may affect spatial and 
non-spatial memory differentially. In addition, non-spatial memory deficit in NOR was reversed 
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by removal of the HFD.  When HFD animals were switched to a LFD, memory deficit was 
corrected within 7 d, indicating that the effect of diet on the brain was transient, rather than a 
result of permanent damage.  In this study, HFD-fed mice also demonstrated a deficit in spatial 
memory measured by the spontaneous alternation paradigm, a measure of hippocampal-based 
learning. Interestingly, Kanoski et al. found after 72 h of HFD feeding rats showed an immediate 
deficit in spatial memory, but not non-spatial memory.  Non-spatial memory remained intact until 
30 d of HFD feeding (38). The radial arm maze, a hippocampal-based learning task, was used to 
test both spatial and non-spatial memory.  NOR is a cortex-based test, suggesting a HFD diet has 
an immediate effect on the cortex-based learning as well as hippocampal-based learning. 
 
We also did not find differences in depressive-like behavior as measured by the forced 
swim test.   Interestingly, HFD-fed mice were less immobile in the forced swim test compared to 
LFD-fed mice after 21 d of feeding.  Several studies have demonstrated decreased depression and 
anxiety in adult HFD-fed animals indicating long-term HFD feeding may be protective for stress-
induced anxiety and depression (35, 39). 
 
The IL-1 cytokine super family (IL-1α, IL-1β, IL1R1, IL1R2, and IL1RA) is associated 
with learning and memory (40-42). IL-1 is required for memory consolidation and learning, 
especially hippocampal-based memory (43).  In fact, IL-1β expression is induced following 
spontaneous alternation testing (44). IL-1 has not been found to play a role in non-spatial memory 
(45). In contrast, LFD- and HFD-fed IL1R1 -/- mice explored a novel object equivocally, 
approximately 50% of total exploration time after 7 and 21 d of feeding, indicating novel object 
recognition is impaired in IL1R1-/- mice regardless of diet. This suggests IL-1 plays a role in non-
spatial memory and learning and is critical in NOR. A previous study that did not find a non-
spatial memory deficit used a visually guided water maze test (45).  The NOR may be a more 
sensitive measure as it does not have a stress component. However, no difference in IL-1 
cytokines was found in the brain after 1 wk of feeding. Slight differences in IL1R2 and IL1RA 
were seen after 21 d of feeding.  IL1R2 mRNA was decreased in the hypothalamus of animals fed 
a HFD for 21 d and IL1RA mRNA was increased in the cortex of mice fed a HFD for 21 d.   
IL1RA competes with IL-1α and IL-1β for binding to the IL-1 receptors in the brain (40, 41). 
Blocking of IL-1 receptors by IL1RA in the hippocampus has been shown to enhance memory 
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retention in avoidance tasks, but does not have an effect in habituation to novel environments 
(40).  We previously demonstrated an increase in IL1RA in the serum of adult HFD-fed mice 
(46). IL1RA also has been shown to be elevated in the serum of obese humans, but the exact role 
of IL1RA in metabolism is unknown (47). Our study suggested elevated IL1RA in obesity may be 
protective against hypoxia (46).  The expression of all other IL1 family cytokines was equivocal 
between diets regardless of time or brain region indicating IL-1 does not play a role in HFD-
induced memory deficit seen in this study.  
 
Obesity is associated with a pro-inflammatory state (48-50), and elevated expression of 
TNF-α and IL-6 in the brain has been associated with cognitive decline (50). However, no 
differences in expression of TNF-α or macrophage activation markers (CD45, CD11b, and F4/80) 
were found in hippocampus, hypothalamus, and cortex of the brain after 7 and 21 d of diet 
feeding. There was a 13% decrease in expression of IL-6 in the hypothalamus of mice fed a HFD 
for 7 d compared to LFD-fed mice and a 15% decrease in expression of IL-6 in the hippocampus 
and a 23% decrease of IL-6 in the cortex of HFD-fed mice after 21 d of feeding.  In contrast to 
our findings, elevation in IL-6 in the brain has been associated with cognitive decline and brain 
disorders (51). Furthermore, IL-6 deficient animals have increased cognition compared to age-
matched wild type mice (52). Studies that have examined the relationship between obesity, IL-6, 
and cognition have done so in an elderly human population or in adult mice fed a HFD for an 
extended period of time (50).  Adipocytes are the main source of pro-inflammatory cytokines in 
the obese state (48, 49). Here, mice are 4-6 wk old and exposed to a HFD for only 7 or 21 d, with 
the HFD-fed group becoming significantly heavier than the LFD-fed group after 12 d of feeding, 
whereas bio-behaviors are affected after 7 d of HFD feeding.   Reaching the pro-inflammatory 
state previously seen in mouse models of obesity may take longer to develop, suggesting an 
alternate pathway for cognitive impairment in a juvenile model. 
 
Alternations in the kynurenine pathway also have been implicated in neuro-cognitive 
deficit, depression, ADHD, and inflammation (51, 53). Interestingly, children with ADHD have 
been found to have elevated levels of serum tryptophan compared to controls, implicating 
alteration of the kynurenine pathway (51).  Additionally, kynurenic acid, a product of the 
kynurenine pathway, can be neuroprotective (54).  Here mice deficient in indoleamine 2,3 
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dioxgenase (IDO-/-) did not differ in performance in the NOR test from control mice, indicating 
IDO is not involved in HFD-induced memory deficit. 
 
We also examined established markers for learning and memory: tyrosine hydroxylase 
(TH), CAMP responsive element binding protein 1 (CREB-1), brain-derived neurotropic factor 
(BDNF), and nerve growth factor (NGF).  While there was no difference in expression of CREB-1 
and TH, expression of BDNF in the cortex was decreased 17% in mice that were fed a HFD for 7 
d.   BDNF has been associated with synaptic plasticity and memory processes including cortex-
mediated object recognition (55-57).   A high fat diet has been shown to decrease BDNF in the 
hippocampus and, furthermore, decreases in BDNF in the hippocampus also have been associated 
with impairment in working memory and decreased spontaneous alternation performance (55, 57). 
BDNF is closely related to the dopamenergic pathway and dopamenergic functions (58, 59).  
Dopamine agonists have been shown to regulate expression of BDNF, indicating dopamine is a 
regulator of BDNF in the prefrontal cortex (55).  Dopamine levels in the cortex are thought to be 
related to cognition, while dopamine levels in the striatum are thought to be related to motivation 
(16). In addition to being part of the mesolimbic dopamine reward system, BDNF regulates food 
intake and body weight (60, 61). 
 
Methylphenidate (MPH), a psychostimulant, is a dopamine transport inhibitor commonly 
used to treat attention deficit hyperactivity disorder (ADHD).  MPH increases the synaptic 
concentration of dopamine and norepinephrine by blocking monoamine transporters in the 
striatum, thus inhibiting reuptake (62). Here, administration of MPH corrected HFD-induced non-
spatial memory deficit in the NOR test. Psychostimulants also may increase norepinephrine and 
serotonin.  Norepinephrine re-uptake inhibitors, desipramine, which is also a selective serotonin 
re-uptake inhibitor, and reboxitene, which does not inhibit serotonin re-uptake did not correct 
HFD-induced memory deficit, indicating in this model that alterations in dopamine and not 
norepinephrine or serotonin have an impact on memory. 
 
ADHD and obesity share similar clinical manifestations such as impaired executive 
function and increased impulsivity, and similar alterations of growth factors and the dopaminergic 
pathway suggesting a common mechanism. This study supports this as HFD feeding immediately 
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increased ADHD-like bio-behaviors and alterations of growth factors related to the dopaminergic 
pathway in the cortex.    The dopaminergic system in the frontal cortex is especially sensitive to 
changes in essential fatty acids (63). Further research is needed to elucidate the mechanism by 











Figure 1: HFD results in weight gain and elevated fasting blood glucose after 7 d of feeding. 
Mice were placed on a low fat diet (LFD) or high fat diet (HFD) at weaning.  Weight (A) and 
fasting blood glucose (B) were measured weekly. White bar indicates LFD and black bar 






Figure 2: HFD increases wheel running but not spontaneous locomotor activity. 
Mice were placed on a low fat diet (LFD) or high fat diet (HFD) at weaning.  To measure activity, 
(A) voluntary wheel running activity (n=16) and (B,C) spontaneous locomotion (n=8) were 










Figure 3: HFD increases reward seeking behavior and anxietal-like behavior, but not depressive-
like behavior.  
Mice were placed on a low fat diet (LFD) or high fat diet (HFD) at weaning. To measure reward, 
anxietal, and depressive-like behavior, mice were subjected to the (A) burrowing test 
(*P≤0.01,n=8; **P ≤ 0.03, n=11), (B) forced swim test (*P ≤ 0.02, n=16), or (C) zero maze 












Figure 4:  HFD decreases novel object recognition and spontaneous alternation. 
Mice were placed on a low fat diet (LFD) or high fat diet (HFD) at weaning. To measure non-
spatial and spatial memory, mice were subjected to either the (A) novel object recognition test 
(*P≤0.001, n=16) or (B) Y-maze test for spontaneous alternation (*P≤0.02, n=16) after 7 or 21 d 







Figure 5: Novel object recognition was restored in HFD-fed mice by feeding a LFD. 
Mice were placed on a low fat diet (LFD) or high fat diet (HFD) at weaning. To determine 
whether novel object recognition could be restored by a LFD, mice were fed a LFD or HFD for 7 
d, subjected to novel object recognition test, then HFD-fed mice were switched to LFD  
(HF->LFD) for 7 d.  Novel object recognition was re-tested after 7 d of additional feeding. (*P ≤ 





Figure 6: IL1R1-/- mice explored a novel object equivocally, while IDO -/- mice explore a novel 
object differentially. 
IL1R1-/- and IDO-/- mice were placed on a low fat diet (LFD) or high fat diet (HFD) at weaning. 
(A) In IL1R1-/- mice, novel object recognition was tested after 7 or 21 d of feeding (n=10-12). 
White bar indicates LFD fed knockout mice and black bar indicates HFD fed knockout mice (B) 
IDO-/- (IDO) or wild type (WT) mice were placed on a low fat (LFD) or high fat (HFD) diet at 
weaning.  Mice were subjected to the novel object recognition test after 1 wk of feeding.  White 
bar indicates LFD-fed wild type mice, black bar indicates HFD-fed wild type mice and light grey 
bar indicates LFD-fed knockout mice and dark grey bar indicates HFD-fed knockout mice. 









Figure 7:  HFD feeding impacts cytokine and growth factor expression in the hippocampus, 
hypothalamus, and cortex.  
Mice were placed on a low fat diet (LFD) or high fat diet (HFD) at weaning.  Brain sections were 
harvested at 7 or 21 d of feeding and cytokine and growth factor mRNA expression were 
measured using qPCR. (A) IL-6 (*P≤0.03, #P ≤ 0.02, n=8) (B) BDNF (*P ≤ 0.006, n=8) (C) NGF 
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(*P ≤ 0.04, n=8) (D) IL-1R2 (*P≤0.02, n=8) (E) IL-1RA (*P ≤ 0.05, n=8) White bar indicates 
LFD and black bar indicates HFD.  LFD at 7 days is set to 1 for comparison. BDNF= brain-









Figure 8: Stimulants correct HFD- induced memory impairment, while anti-depressants do not. 
Mice were fed a low fat diet (LFD) or high fat diet (HFD) for 1 wk.    The novel object test was 
performed after the administration of the following IP: (A) reboxitine (n=8), (B) despiramine 
(n=8), (C) methylphenidate (n=8), (D) caffeine (n=4).  White bar indicates vehicle-injected LFD-
fed mice, black bar indicates vehicle-injected HFD-fed mice, light grey bar indicates drug-
injected LFD-fed mice and dark grey bar indicates drug-injected HFD-fed mice. Differences in 
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Modulation of outcomes pertaining to diabesity by dietary fiber 
4.1 Introduction 
Dietary fiber (DF) has been heralded as a solution to the diabesity crisis, but research 
pertaining to obesity and diabetes is inconsistent (1-8).  Furthermore, the mechanism by which 
DF reduces the risk of these conditions remains to be elucidated.  Epidemiological (9-12) and 
animal studies (2, 3, 13-16) lend evidence toward an inverse relationship between DF intake and 
weight, while data from human intervention trials has been less convincing (7, 17-20). 
Additionally, statistically significant weight loss resulting from DF intake in human trials is not 
always clinically relevant (18).  DFs appear to be most effective in weight reduction in 
individuals who are obese or overweight at baseline and when used in combination with a 
calorie-restricted diet (11, 17). The relationship between DF intake and diabetes is also unclear.  
Animal (2, 21) and human (6, 7) research indicates a protective effect of soluble DF against 
hyperglycemia, but this relationship is not reflected in population-based studies (22).  
The effect of DF on weight and blood metabolites may be dependent on DF dose, type, 
and the intrinsic properties of the DF. The characterization of DF and the role of DF in 
metabolism are extensively reviewed in Chapter 2. Briefly, DF is classified by solubility, degree 
of microbial fermentation, and viscosity (19). Through these physical properties, DF confers 
health benefits by reducing macro-nutrient absorption through increased viscosity of luminal 
contents, delayed gastric emptying, and by increased fecal bulking (1, 23, 24). As an example, 
pectin is a soluble, viscous, and highly fermentable DF that is completely digested in the colon 
(25). Cellulose, on the other hand, is an insoluble, non-fermentable DF that is virtually 
indigestible. Additionally, cellulose binds water in the large intestine, increasing fecal bulk (25). 
Other fibers such as resistant starch and oligosaccharides fall somewhere in the middle on the 
solubility and fermentation scales. Fructooligosaccharides are indigestible in the upper 
gastrointestinal tract, but are rapidly fermented by microbes in the proximal colon.  Resistant 
starches also are indigestible and fermentable, but are more slowly degraded and undergo 
fermentation in the distal colon (26, 27).   
 
Here, we re-visit pectin, a main focus of fiber research in the 1970’s, as well as examine 
resistant starch and fructooligosaccharides, two relative newcomers to fiber research, to re-
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explore the role of DF in the prevention of weight gain and hyperglycemia.  We compare the 
ability of pectin, resistant starch, fructooligosaccharides, and cellulose to slow weight gain when 
added to a high-fat diet (HFD).  In addition, we explore pectin’s role in the prevention of 
diabesity by examining the capability of pectin to bind lipids and alter intestinal morphology. 
 
4.2 Methods 
Animals- C57BL/6J male mice (3 wk old) were purchased from Jackson Laboratories (Bar 
Harbor, ME).   MYD88-/-, TLR2-/-, TLR4-/-, IL1R1-/-, and IL4-/- male mice were bred in house 
and weaned at 3-4 wk. C57Bl/6J, IL4-/-, and IL1R1-/- mice were group housed (8 per cage) in 
large standard shoebox cages (length 28 cm; width 17 cm; height 12.5 cm).  MYD88-/-, TLR2-/-, 
and TLR4-/- mice were group-housed in small standard shoebox cages housed in a ventilated 
cage system.  Mice were allowed free access to food and water.  Housing temperature (72°F) and 
humidity (45-55%) were controlled, as was a 12/12 h reversed dark-light cycle (2200-1000 h).  
Animal use was conducted in accordance with Institutional Animal Care and Use Committee 
(IACUC)-approved protocols at the University of Illinois. 
 
Diets - Mice were fed open source uniform-base diets containing either 10% calories from fat + 
5% cellulose by weight (LF5C, D12450B) or 60% calories from fat + 5% cellulose by weight 
(HF5C, D12492) or a specially formulated diet containing 10% calories from fat + one of the 
following DF by weight: 5% pectin (LF5P, D10101303), 10% pectin (LFP, D06082202), 10% 
cellulose (LFC, D06082201), 10% Orafti P95 fructooligosaccharides (LFF, D10032401), 10% 
High-Maize 260 resistant starch (LFRS, D10032403), 5% pectin + 5% cellulose (LFPC, 
D10040401 ) or 60% calories from fat + one of the following DFs by weight: 5% pectin (HF5P, 
D10101304), 10% pectin (HFP, D08111803), 10% cellulose (HFC,D07102501), 10% Orafti P95 
fructooligosaccharides (HFF, D10032402), 10% High-Maize 260 resistant starch (HFRS, 
D10032404 ), or 5% pectin + 5% cellulose (HFPC, D10040402).  Diet composition is outlined in 
Table 1.  Energy values were calculated using the following conversion factors:  4 for protein, 4 
for carbohydrates, and 9 for fat.   Mice were fed ad libitum for study duration. All diets were 




Weight and blood metabolites- Mouse weight was recorded weekly using an Adventurer Pro 
digital scale (Ohaus, Parsippany, NJ).  To measure the effect of diet on fasting blood glucose, 
mice were fasted for 8 h prior to tail blood collection. Fasted mice were provided water ad 
libitum.  Mouse tail blood glucose was recorded weekly using a AlphaTRAK blood glucose 
monitor (Abbott, Abbott Park, IL) after the tail was cleaned with 70% ethanol and lanced with a 
sterile No. 10 surgical scalpel blade (Feather, Osaka, Japan).  To measure the effect of diet on 
glucose and insulin properties, the intraperitioneal glucose tolerance test (IPGTT) and the 
intraperitoneal insulin tolerance test (IPITT) were used.  For IPGTT, mice were fasted for 4 
hours prior to testing.  Mice then were injected intraperitoneally with a 30% glucose solution.  
For IPITT, fed mice were injected intraperitoneally with 0.75U/kg insulin. For both the IPGTT 
and the IPITT, baseline blood glucose was tested prior to injection and at 15, 30, 45, 60, 90, 120, 
and 180 min after injection using methods described above. 
 
Food intake and fecal collection- To measure food intake and to collect feces, 6 mice of each 
diet group were single housed in standard metal metabolic cages with wire bottoms after 10 wk 
of feeding. Food intake was recorded daily for 6 d to determine voluntary food intake.  
Beginning on d 7, mice were given 90% of their voluntary food intake for the next 7 d.  Feces 
were collected and pooled per mouse daily.  Mice were weighed every other day.  After the 14
th
 
day, pooled fecal samples were weighed to obtain wet weight and then dried at 57
0
C for 2 d. 
Fecal samples then were ground through a 0.5 mm screen in a Wiley mill (Thomas Scientific, 
Swedesboro, NJ )  or a coffee grinder (Mr. Coffee, Shelton, CT) .  A 250 mg aliquot of each 
sample was heated overnight at 105
0
C and then weighed to determine dry matter content.   
 
Sample collection and histology- Mice were sacrificed after 12 wk of feeding by CO2 
asphyxiation.  Blood was collected by cardiac puncture into a 2 mL Eppendorf tube (Eppendorf, 
Hamburg, Germany) and placed in ice.  An abdominal incision then was made and mice were 
perfused with 1% phosphate-buffered saline (PBS) to remove blood contaminants, and the liver, 
whole intestine, cecum, and visceral adipose were removed and immediately weighed. Intestines 
were divided into sections: small intestine, large intestine, and cecum.  Each section was 
weighed whole and after removal of intestinal material. Cecal content was removed and weighed 





weighed to determine dry matter content.  The other half of the samples was processed 
immediately for short chain fatty acid (SCFA) analysis.  
Ileal sections were taken from small intestinal segments and sliced open length-wise. Ileal 
samples were fixed in 10% formalin and were processed by the Histology Lab at the College of 
Veterinary Medicine at the University of Illinois.  Briefly, tissues were embedded in paraffin.  
One section was cut per paraffin block and sections were adhered to slides and stained using 
hematoxylin and eosin (H&E).  Liver and ileum slides were photographed and images were 
captured using the Nanozoomer Digital Pathology System (Hamamatsu Photonics, Hamamatsu 
City, Japan).   
 
Chemical analyses- Cecal contents were placed in micro-centrifuge tubes and acidified with 
6.25% m-phosphoric acid and held at room temperature for 30 min after which they were frozen 
at -20
0
C overnight.  Samples then were thawed and centrifuged at 13,000 x g for 10 min.  
Supernatant was transferred to gas chromatography vials and acetate, butyrate, propionate, 
valerate, isovalerate, and isobutyrate were measured by gas chromatography (28). 
Diet and feces were analyzed for dry matter (DM), organic matter (OM), and ash (29).  Total 
lipid content of feces was determined by acid hydrolysis followed by ether extraction according 
to the methods of the American Association of Cereal Chemists (30).  Gross energy of fecal 
samples was determined by oxygen bomb calorimetry according to Parr Instrument Manuals 
(Parr Instrument Co., Moline, IL;  No 203M, 205M, 207M, 246M). 
 
Statistical analysis- Data analysis was conducted using Sigma Plot 11.2 (Systat Software, 
Chicago, IL). Food intake, energy intake, SCFA, and weight data were subjected to 1-way 
ANOVA to determine the main effect of diet. Post-hoc means separation using a Tukey 
adjustment was performed to determine differences among diet groups. When the test for 
normality failed (P<0.05), the Kruskal–Wallis one-way analysis of variance by ranks was 
performed followed by a Tukey adjustment in the case of equal groups and a Dunn’s adjustment 
when group size was not equal.  Statistical significance was assumed at P<0.05.  Data were 






Pectin delays weight gain when added to a high fat diet compared to cellulose at a 10% addition, 
but not less.   
Figure 1 shows that pectin is protective against weight gain when added to a HFD at a level of 
10%.  Mice fed a HFD + 10% pectin (HFP) gained less weight than mice fed a HFD + 10% 
cellulose (HFC) after 12 wk of feeding (14.21g±1.44 vs. 24.81g±1.31, n=24-25, P<0.05).  
Beginning at wk 1, mice fed HFC were heavier than mice fed LFC, LFP, and HFP (P<0.05). 
Beginning at wk 4, mice fed HFP weighed more than both LFD groups (P<0.05). HFP weighed 
less than HFC at all time points after baseline (P<0.05).  Figure 2 shows that supplementation of 
5% pectin to a HFD is not protective against weight gain.  Mice were fed a HFD or LFD with the 
addition of 5% pectin (5P) or 5% cellulose (5C).  By wk 3, both HFD groups (HF5C and HF5P) 
weighed more than LFD groups (LF5C and LF5P) (n=8, P<0.05). There was no significant 
difference in body weight between HF5C and HF5P or LF5C and LF5P at any time point. To 
determine if the total percent of fiber contributed to the prevention of weight gain and not the 
amount of pectin specifically, mice were fed a HFD or LFD with 5% pectin + 5% cellulose (PC) 
(Figure 3).  HFPC slowed weight gain, but did not prevent weight gain to the same extent as 
HFP.  HFC fed mice were significantly heavier than LFD fed mice after 3 wk of feeding, while 
HFPC mice were not significantly heavier than LFD groups until week 5 of feeding.  After 12 
wk of feeding, HFPC was not significantly different in weight than HFP or HFC (n=8). 
 
Fructooligosaccharides and resistant starch do not protect against weight gain when added to a 
high fat diet. 
To determine if weight gain was due to an intrinsic property of pectin or was due to the solubility 
or fermentation of the fiber, mice were placed on a HFD or LFD with 10% 
fructooligosaccharides (F) or 10% resistant starch (RS).   Figure 2 shows mice fed HFF, HFRS, 
and HFC were s heavier than HFP beginning at wk 1  (P<0.05, n=8). 
Pectin is not protective against weight gain in all knockout strains. 
To explore the mechanism by which pectin affects weight gain, IL4-/-, IL1R1-/-, TLR4-/-, 
TLR2-/-, and MYD88-/- mice were fed a HFP, HFC, LFP, or a LFC diet for 12 wk (Table 4).    
In IL1R1-/- mice, there was no significant difference in weight among diet groups until wk 12 of 
feeding.  At wk 12, HFC-fed mice were heavier than HFP and LFP groups (P<0.05).  HFC-fed 
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IL4-/- mice were heavier than all other diet groups beginning at 3 wk of feeding (P<0.05). Pectin 
delayed weight gain in HFD-fed MYD88 -/- mice.  After 6 wk of feeding, HFC-fed mice were 
heavier than LFP-fed mice (P<0.05).  At 9 wk, HFC was heavier than both LFD groups, while 
there were no weight differences between HFP and any other group (P<0.05).  At wk 12, HFP-
fed mice were heavier than LFP-fed mice, while there was no difference in weight between HFP- 
and LFC- or HFC-fed mice (P<0.05). Pectin did not have an effect on weight in TLR4-/- or 
TLR2-/- mice. There were no significant differences in weight between TLR4-/- or TLR2-/- 
HFC- and HFP-fed mice at any time point.  After 12 wk of feeding, HFD groups were heavier 
than LFD groups in both TLR4-/- and TLR2-/- mice (P<0.05).    
 
Pectin decreases hyperglycemia but not hyperinsulinemia in high fat diet-fed mice. 
Table 3 shows that fasting blood glucose concentrations were elevated  in the HFC group 
compared to HFP, LFP, and LFC groups at 3 wk of feeding (n=8, P<0.05).  There was no 
difference between HFD and LFD groups at 12 wk.  The IPGTT data showed elevated glucose 
concentrations in the HFC group compared LFP and LFC (n=6, P<0.05).  There was no 
difference in blood glucose concentrations between the HFP group and LFD groups, indicating a 
protective effect of pectin (Figure 5A).  The IPITT data showed no difference in glucose 
concentration at any time point among diet groups (n=6) (Figure 5B). 
 
Pectin-fed mice consume more calories per day than cellulose-fed animals, while there was no 
difference in intake between resistant starch and fructooligosaccharide-fed animals. 
Figure 6 demonstrates food intake differences among diet groups.  Average daily food intake 
was lower in HFC-fed mice compared to LFP-, LFC-, and HFP-fed mice (n=6, P≤0.02).  Daily 
calorie intake of HFC-fed mice was less than LFC- and HFP-fed mice (P≤0.006).  Average daily 
food intake was higher in LFRS- and LFF- fed mice than in HFRS- and HFF-fed mice (n=6, 
P≤0.03).  There was no difference in calorie intake between RS- and F-fed mice regardless of fat 
content. 
Cecal SCFA and BCFA profiles differ among diets. 
Table 4 depicts the differences in cecal contents of SCFA and BCFA among diets.  HFP-fed 
mice had 70% less cecal isobutyrate than LFC-fed mice (P≤0.05), 68% less cecal isovalerate 
than LFC-fed mice (P≤0.05), 56% less cecal isovalerate than LFP-fed mice (P≤0.05), 160% less 
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cecal valerate than LFC-fed mice (P≤0.05), and 134% greater cecal acetate than HFC-fed mice 
(P≤0.05).  Cecal butyrate was 54% higher in LFP-fed mice compared to HFP-fed mice 
(P≤0.001), 73% higher than HFC-fed mice (P≤0.001), and 52% higher than LFC-fed mice 
(P≤0.001).  There was 66% less cecal propionate in LFP-fed mice compared to HFC-fed mice 
(P≤0.05).  HFF-fed mice had 68% less cecal isovalerate than LFF-fed mice (P≤0.05), 94% less 
than LFRS-fed mice (P≤0.05), and 70% less than HFRS-fed mice (P≤0.05).  HFRS-fed mice had 
101% less cecal propionate than LFRS-fed mice (P≤0.05), 134% less cecal propionate than LFF-
fed mice, 338% less butyrate than LFF-fed mice (P≤0.05), and 245% less cecal butyrate than 
HFF-fed mice (P≤0.05).  LFRS-fed mice had 47.2% less cecal valerate than HFRS-fed mice 
(P≤0.05).  
 
Fecal lipid and energy content are greater in pectin-fed mice  
Figure 7A shows that fecal lipid content was greater in pectin-fed mice compared to cellulose-
fed mice (n=6, P≤0.001). Figure 7B shows fecal lipid content was greater in resistant starch-fed 
animals compared to fructooligosaccharide-fed animals (n=6, P≤0.001).  Figure 7C shows fecal 
energy content was greater in HFP-fed mice compared to HFC-fed mice (n=6, P≤0.001).   
 
Pectin reduces visceral fat and liver weight, and increases cecal weight and intestinal length 
Table 5 shows pectin supplementation reduces accumulation of visceral fat.  Weight of visceral 
fat from HFP-fed mice was not significantly different than HFC or LFD groups, while visceral 
fat in HFC-fed mice was greater than LFD-fed animals (n=7-8, P<0.05).  HFP decreased liver 
weight compared to HFC (n=7-8, P=0.04).  Pectin also increased the weight of the cecum 
(empty) compared to cellulose (n=7-8, P<0.05).  Pectin increased cecal content weight in both 
HFP and LFP, but the difference was only significant between LFP vs. HFC (n=7-8, P<0.05).  
LFP increased total intestinal length compared to other diets (n=7-8, P≤0.04). 
 
4.4 Discussion 
 Several rodent studies have demonstrated a protective effect of soluble fiber against 
weight gain (2, 3, 13, 15, 16, 31).  In support of these findings, we found that animals fed a HFD 
supplemented with pectin gained less weight then mice fed a cellulose-supplemented diet. Pectin 
supplementation also resulted in decreased accumulation of visceral fat compared to cellulose.  
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Hove et al. found pectin to decrease both weight and food intake in rats when added to both a 
low protein and high protein diet, while cellulose supplementation increased weight and food 
intake only when added to a low protein diet (31).  Surprisingly, in this study, mice fed a HFD + 
cellulose (HFC) had decreased energy intake compared to LFD + cellulose (LFC)- and HFD + 
pectin (HFP)-fed mice. This could be an artifact of study design, as HFC-fed mice were 
significantly heavier than other diet groups and may have been more uncomfortable on wire 
bottom cages resulting in anxiety and decreased food intake.  This is not likely the case as weight 
gain on resistant starch and fructooligosacchrides treatments did not alter calorie intake. 
Interestingly, pectin was only protective at the level of 10%.   Supplementation of 5% pectin 
with or without the addition of 5% cellulose was not effective in prevention of weight gain. This 
may indicate a dose-response effect, as pectin is only effective in weight prevention at higher 
doses. Unfortunately, the weight benefit from pectin noted in rodents may not carry over to 
humans.  In a clinical trial, 4 wk supplementation of 15 g/d of pectin did not decrease weight 
compared to 12 g/d of cellulose (32). This may be due to the dose of pectin administered in this 
study.  Supplementation of some DFs may not be able to be delivered at doses high enough to be 
effective in humans. Intake of large amounts of soluble DF may result in rapid fermentation and 
excessive production of gases leading to discomfort and gastrointestinal distress (33).  
 
To determine if pectin’s delay of weight gain in HFD-fed mice was due solely to the 
solubility of pectin, we explored the effect two additional soluble fibers, resistant starch and 
fructooligosaccharides, on the prevention of weight gain.  Both are fermentable fibers, but 
fructooligosaccharides are quickly fermented, while resistant starch is slow to degrade.    Mice 
fed a HFD supplemented with either 10% fructooligosaccharides or 10% resistant starch 
exhibited a similar pattern of weight gain to mice supplemented with 10% cellulose.  There was 
no difference in energy intake between fructooligosaccharide and resistant starch diet groups.  
This suggests that the ability of pectin to delay weight gain in combination with a HFD may 
extend beyond solubility and ability to delay gastric emptying.  
 
Reduced weight gain in HFP-fed mice compared to HFC-fed mice may be due, in part, to 
increased fecal lipid excretion. This study supports previous findings of increased fecal lipid 
excretion after pectin supplementation in both animals and humans (34-36).   In a human study, 
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15 g of citrus pectin for 3 wk increased fecal lipid excretion by 44% (35).  In fact, pectin is 
capable of binding 4 times its weight in lipid through hydrogen bonding of methloxy-carbonyl 
groups (37).  Extent of lipid binding is dependent on the degree of methylation of pectin.  The 
dose-response effect of pectin on weight reduction may be related to lipid-binding capacity. The 
larger percentage of pectin in the diet, the larger capacity of pectin to bind lipids.    
 
The prevention of weight gain by pectin may not be solely due to increased lipid binding 
capacity.   In ILIR1, IL-4, TLR2, TLR4, and MYD88 knockout mice fed a HFD supplemented 
with pectin and cellulose, pectin was not equally protective in the prevention of weight gain. IL-
1, IL-4, and members of the TLR/ MyD88 signaling pathway may all play a role in weight 
regulation.   Dis-regulation of the pro-inflammatory cytokine, IL-1, has been shown to result in 
weight modulation (38, 39).  IL1RA (IL-1 receptor antagonist)-deficient mice have decreased fat 
mass compared to wild type control mice (38) while IL1R1 (IL-1 receptor)-deficient mice 
(IL1R1-/-) are prone to late onset obesity compared to controls (39).  Here, IL1R1-deficient mice 
fed a HFD or LFD supplemented with pectin or cellulose did not differ in weight until wk 12.  At 
wk 12, HFC-fed mice were significantly heavier than HFP- and LFD-fed groups.  Weight 
differences between HFC and LFD groups occur by 3 wk in wild type mice.  Decreased 
functional IL-1 may initially be protective against diet-induced obesity.  Although Garcia et al. 
found IL1R1-/- mice to be at risk for the development of obesity, weight differences between 
IL1R1-/- mice and controls were not seen until after 4 mo of age (39). A second pro-
inflammatory cytokine, IL-4, also has been implicated in the pathogenesis of obesity.  
Administration of IL-4 in combination with a HFD feeding exacerbates weight gain in rats (40).  
In our study, IL-4-deficient mice fed a HFC diet became significantly heavier than HFP- and 
LFD-fed mice at 3 wk of feeding and followed a similar weight gain pattern to wild type mice. 
Therefore, the protective effect of pectin does not appear to involve a IL-1 or IL-4 mechanism.  
 
Members of the toll-like receptor (TLR) signaling pathway also have been linked to 
obesity. There are 10 members of the TLR family in humans (41). TLR4 is a receptor located on 
monocytes that detects lipopolysaccharide (LPS).  In wild type mice, HFD-feeding increases 
blood monocytes, but decreases surface TLR4 expression (42). TLR4-deficient (TLR4-/-) mice 
have been found to maintain low body fat regardless of diet (43). In contrast, this study found 
70 
 
HFD-fed mice to be significantly heavier than LFD-fed mice, regardless of fiber content 
beginning after 3 wk of feeding.  Interestingly, pectin was not protective against weight gain in 
the TLR4-/- mice, suggesting the TLR4 receptor may be necessary for pectin to reduce weight 
gain. TLR2 deficient (TLR2-/-) mice also have been shown to be protected from HFD-induced 
weight gain (44).   In this study, although differences in weight among diet groups did not occur 
until 6 wk of feeding, by wk 12, HFD groups were significantly heavier than LFD groups, 
suggesting the TLR2 receptor also may play a role in reduction of weight gain by pectin.   
 
TLR4 and TLR2 are components of the MyD88-dependent signaling pathway (41).  
MyD88 also has been reported to be essential in the progression of diet-induced obesity.  CNS-
specific MyD88 knockout mice (MyD88-/-) are protected from HFD-induced weight gain (45). 
Here, MyD88 deficiency was found to delay weight gain in HFD-fed mice.  HFC-fed MyD88-/- 
mice were not significantly heavier than LFD-fed MyD88-/- mice until wk 9.  At wk 9, HFP-fed 
mice were not significantly different from either HFC- or LFD-fed mice, indicating that although 
pectin may offer some protection, MyD88-/- also may be a part of the mechanism of inhibition 
of weight gain by pectin.   
 
In addition to conferring a weight benefit, DF improves glycemic control, fasting blood 
glucose, and insulin sensitivity by altering carbohydrate absorption through the formation of 
viscous gels and inhibition of glucose transport across the intestinal membrane (1, 46, 47).  Here, 
10% pectin supplementation slowed HFD-induced elevation in fasting blood glucose 
concentrations after an 8 h fast. Pectin supplementation also improved glucose tolerance 
compared to cellulose, but did not affect insulin tolerance. This may indicate pectin 
supplementation prevents or slows the pre-diabetic state noted in cellulose-supplemented mice.  
The ability of soluble fiber to lower blood glucose is inconsistent in animal studies. Psyllium and 
sugar cane fiber decreased fasting blood glucose concentrations in rodents, while apricot fiber 
and okara did not (21, 48, 49). In human studies, several soluble fibers including pectin and guar 
gum improved oral glucose tolerance (50). Soluble β-glucan improved glucose tolerance and in 
contrast to our findings, decreased serum insulin concentrations after supplementation at a 2 and 
4% level (2). Inconsistencies in results may be due to type of fiber administered and dosage of 
DF.  DF varies in intrinsic characteristics that may result in differences in physiologic effect.  
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Prevention of diabesity by DF may be due, in part, to production of SCFAs.  Fermentable 
DFs are partially or completely fermented in the intestine to SCFAs: butyrate, propionate, and 
acetate (51). In humans, pectin supplementation increased total SCFAs compared to cellulose 
(52). Here, pectin increased the cecal concentration of acetate, propionate, and butyrate 
compared to cellulose.  In contrast, in a study in rats, pectin increased acetate, but not butyrate or 
propionate (53).  This discrepancy may be due to study design Fukunaga et al. administered 
pectin in an enteral formula as opposed to a component in a pellet-based diet.  Resistant starch 
and fructooligosaccharide groups did not differ in cecal acetate concentration, but had significant 
differences in concentrations of cecal propionate and butyrate. This is consistent with other 
studies which found that fructooligosaccharides and resistant starch increased butyrate and 
decreased acetate (33).  SCFAs may affect weight and diabetes-related outcomes by modifying 
the expression of key genes involved in lipid and carbohydrate metabolism (54-57).  As an 
example, propionate decreased fatty acid and cholesterol synthesis by blocking the incorporation 
of acetic acid into fats and sterols (62).  Furthermore, DF intake alters microbiota populations 
that can directly impact lipid and cholesterol metabolism by enhancing bile acid deconjugation 
(58, 59).   Fermentable DF intake also has been shown to alter genes and hormones related to 
carbohydrate metabolism such as pro-glucagon and glucagon-like peptide 1 (13, 23, 60).  This 
may occur as a result of the influence on DF on intestinal morphology, specifically augmentation 
of L-cells (13). 
 
Intake of DF also has trophic effects on the intestine, altering ileum length and weight 
and changing the morphology of the small intestine (53, 61, 62). Both pectin and cellulose have 
been shown to increase villus height and width compared to animals fed a control diet (62, 63).  
Pectin, in particular, has been shown to increase villus length compared to cellulose (61).  In 
chickens, diets supplemented with pectin have been shown to increase the percentage of tongue-
shaped villi and decrease the shape of ridge-shaped villi in the ileum compared to non-pectin 
supplemented diets (64).  Compared to a fiber-free diet, pectin significantly increased length and 
weight of the small intestine, cecum, and colon in rats fed an enteral diet for 4 wk (53).  The 
extent of these trophic effects also may depend on degree of methylation. Here, pectin 
significantly increased total intestinal length. Trophic effects of pectin could be the result of 
increased brush border enzymes or due to changes in SCFA production.  Pectin has been shown 
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to increase enteroglucagon and glucagon-like peptide- 2, both of which have been shown to have 
trophic effects on the intestine (53).  
 
In addition to changes in the morphology of the intestine, DF supplementation of rodents 
decreased adiposity and liver weight (2, 49, 65). β-glucan has been shown to decrease liver and 
adipose tissue weight compared to control-fed animals (2).  Here, pectin reduced fat 
accumulation compared to cellulose.  HFC-fed mice had greater visceral fat compared to LFD-
fed groups, while there was not a significant difference in amount of visceral fat between HFP-
fed mice and LFD-fed groups.   
 
Not all soluble DFs are equal.   This study supports current research that shows 
contradictions in the beneficial effects of fiber, particularly as regards weight reduction.  Pectin 
prevented weight gain in HFD-fed mice, while resistant starch and fructooligosaccarides, both 
soluble and fermentable fibers, did not.   Differences among DF could be due to fermentation 
patterns or lipid binding capacity.  Perhaps more interestingly, this study suggests that toll-like 
receptor signaling may be involved in both delaying diet induced obesity and the mechanism by 










CHO Cellulose Pectin FOS RS 
High fat 5% 
cellulose  
(HF5C) 
5.24 34.9(60) 26.2(20) 26.3 (20) 50(0)    
High fat 5% 
pectin  
(HF5P) 




4.91 32.7(60) 24.5 (20) 24.7 (20) 50(0) 52.5(0)   
High fat pectin  
(HFP) 




4.89 32.6(60) 24.5(20) 24.6 (20)     
High fat FOS 
(HFF)  
4.89 32.6(60) 24.5(20) 24.6 (20)   105(0)  
High fat RS  
(HFRS) 
4.89 32.6(60) 24.5(20) 24.6 (20)    105(0) 
Low fat 5% 
cellulose  
(LF5C) 
3.85 4.3 (10) 19.2(20) 67.3 (70) 50(0)    
Low fat  5% 
pectin  
(LF5P) 




3.66 4.1 (10) 18.3(20) 64.1 (70) 50(0) 52.5(0)   
Low fat pectin 
(LFP) 




3.67 4.1 (10) 19.2(20) 67.3 (70) 100(0)    
Low fat FOS 
(LFF)  
3.85 4.3 (10) 18.3(20) 64.0 (70) 50(0)  105(0)  
Low fat RS 
(LFRS) 
3.65 4.1 (10) 18.3(20) 64.0 (70)    105(0) 
Table 4:  Macronutrient composition of research diets. Values for fat, protein, carbohydrate, and 
dietary fiber are presented as g/4057 kcal (% kcal).  CHO= carbohydrate, FOS= 
fructooligosaccharides, RS= resistant starch.  *conversion factors used:  4 for protein, 4 for 







Figure 9:  10% pectin slows weight gain. 
Mice were placed on a high fat (HF) or a low fat (LF) diet containing either 10% pectin (P) or 
10% cellulose (C). * denotes significant differences in weight between HFC- and HFP-fed mice 








Figure 10:  5% pectin was not protective against weight gain 
Mice were placed on a high fat (HF) or a low fat (LF) diet containing either 5% pectin (5P) or 
5% cellulose (5C).  Mice were weighed weekly.  *indicates a significant difference between HF 





Figure 11:  A combination of pectin and cellulose did not protect against weight gain to the 
same extent as 10% pectin. 
Mice were placed on a high fat (HF) or a low fat (LF) diet containing either 10% pectin (P), 10% 
cellulose (C), or 5% pectin + 5% cellulose (PC).  * indicates point at which HFC fed mice 
became heavier than all 3 LFD groups.   # indicates the point at which HFCP became heavier 
than all 3 LFD groups. Mice were weighed weekly (n=8, P<0.001).   
 







Figure 12: Resistant starch and fructooligosaccharides are not protective again weight gain. 
  Mice were placed on a high fat (HF) or a low fat (LF) diet containing either 10% pectin (P), 
10% cellulose (C), 10% resistant starch (RS), or 10% fructooligosaccharides (F).   Mice were 
weighed weekly.  *denotes the time point where HFRS-, HFF-, and HFC-fed mice became 




Knockout Diet Baseline 3 weeks 6 weeks 9 weeks  12 weeks 
IL-4-/- 
      
 
LFP 11.6±0.9 22.5±0.3a 26.1±0.6a 27.3±0.8a 29.0±0.8ab 
 
LFC 14.3±1.4 22.4±0.7a 25.1±0.6a 26.8±1.2a 26.8±0.6a 
 
HFP 11.4±0.6 22.1±0.7a 26.1±1.0a 30.2±1.0a 31.7±1.3b 
 
HFC 14.7±1.2 25.2±0.6b 30.4±1.0b 35.0±1.4b 39.3±2.0c 
       IL1R1-/- 
      
 
LFP 14.8±1.4 22.5±0.5 25.5±0.4 27.4±0.4 28.8±0.4a 
 
LFC 15.0±0.7 22.8±1.2 25.3±1.3 28.8.0±1.3 29.9±1.7ab  
 
HFP 14.2±2.3 21.9±1.1 24.7±0.7 26.9±0.5 28.0±0.8a 
 
HFC 14.3±1.5 24.6±1.0 30.2±1.3 32.6±1.7 37.3±2.2b 
       TLR4-/- 
      
 
LFP 7.3±0.6 15.9±1.2a 18.9±1.3a 21.2±0.9a 22.0±0.9a 
 
LFC 9.5±0.8 18.8±1.1ab 21.2±1.1ac 23.8±0.8ab 24.0±1.3a 
 
HFP 8.4±0.9 19.7±0.7b 23.0±0.9b 25.1±1.0b 28.0±0.8b 
 
HFC 7.9±1.1 18.9±0.7ab 22.9±0.7bc 25.8±0.5b 28.7±0.6b 
       TLR2-/- 
      
 
LFP 9.6±0.4 17.7±0.6 20.4±0.5a 21.8±0.6a 22.4±0.5a 
 
LFC 9.7±0.9 18.3±1.1 21.7±0.6ab 23.4±0.7ab 24.4±0.6a 
 
HFP 10.5±1.2 18.9±0.6 22.6±0.9ab 25.8±1.1bc 27.6±1.1b 
 
HFC 9.9±1.9 20.4±0.7 24.2±0.8b 27.5±1.1c 29.8±1.1b 
       MyD88-/- 
      
 
LFP 14.4±1.5ab 20.2±0.9 22.2±0.8a 24.5±0.9a 24.8±0.9a 
 
LFC 16.1±1.8a 21.9±1.0 24.2±0.9ab 26.1±0.8a 27.4±0.8ab 
 
HFP 10.6±1.3b 19.7±1.3 24.1±1.0ab 27.9±1.0ab 30.7±1.1bc 
 
HFC 11.5±0.4b 21.2±0.8 27.0±1.6b 31.2±2.7b 34.2±1.9c 
 
Table 5:     Pectin is not protective against weight gain in all knockout strains.  
IL1R1-/-, IL4-/-, TLR4-/-, TLR2-/-, and MYD88-/- mice were placed on a high fat (HF) or a low 
fat (LF) diet containing either 10% pectin (P)  or 10% cellulose (C). Mice were weighed weekly.  
Different letters represent significant differences among diet groups. Values are presented as 
means ± SEM.  P<0.05.   IL1R1-/-: n=8-12; IL4-/- n=8-10; MYD88-/- n=8-12; TLR4-/- n= 7-12; 





Table 6: Pectin blunts high fat diet-induced hyperglycemia  
Mice were placed on a high fat (HF) or a low fat (LF) diet containing either 10% pectin (P) or 
10% cellulose (C). Blood samples were collected from the tail after 8 h of fasting. Fasting blood 
glucose was measured weekly. Values presented as means ± SEM. Letters indicate significant 
differences (n=8, P≤0.05).  LFP= 10% fat + 10% pectin, LFC= 10% fat + 10% cellulose, HFP= 
60% fat + 10% pectin, HFC= 60% fat + 10% cellulose.   
Baseline Week  1   Week  3  Week  6  Week  9 Week  12  
mg/dL 
92.8±14.2a 109.9±18.9 103.6±14.8a 94.4±9.5a 106.7±7.1a 113.1±5.1a 
126.5±12.6ab 145.8±16.5 117.3±18.7a 110.5±3.1a 158.8±14.4ab 114.6±5.1a 
141.4±7.4b 111.1±25.5 124.0±19.7a 160.0±7.3b 190.6±8.4bc 142.8±7.1b 








Figure 13:   Pectin prevents hyperglycemia but not insulinemia 
Mice were placed on a high fat (HF) or a low fat (LF) diet containing either 10% pectin (P) or 
10% cellulose (C). Both the IPGTT and IPITT were performed after 12 wk of diet feeding.   (A) 
IPGTT was performed after a 4 h fast. (B) IPITT was performed on fed mice. Values presented 
as means ± SEM. LFP= 10% fat + 10% pectin, LFC= 10% fat + 10% cellulose, HFP= 60% fat + 
10% pectin, HFC= 60% fat + 10% cellulose.  Different letters indicate significant differences 
among treatments (n=6, P<0.05).   
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Figure 14 (A-D):   High fat pectin-fed animals have a greater energy intake than cellulose- fed 
animals 
Mice were placed on a high fat (HF) or a low fat (LF) diet containing either 10% pectin (P), 10% 
cellulose (C), 10% resistant starch (RS), or 10% fructooligosaccharides (F).   After 10 wk of 
feeding, mice were placed in metabolic cages and food intake was recorded daily for the first 6 d 
(A, B).  Energy intake was calculated from daily food intake (C, D). Different letters indicate 








LFP 241.3±27.5a 28.9±2.6a 52.2±6.8a 171.9±66.2a 2.9±0.4ab 2.1±0.2a 1.7±0.2ab 31.4±12.3a 
LFC 147.6±16.1ab 18.1±1.8ab 25.1±2.3b 101.8±39.7ab 3.4±0.5a 2.9±0.5a 3.1±0.5a 18.4±7.1ab 
HFP 239.6±66.2a 16.7±2.2ab 24.1±2.6b 149.5±57.9b 1.7±0.3b 0.9±0.06b 1.2±0.2b 14.8±5.7b 
HFC 105.3±39.5b 9.9±3.4b 13.8±3.1b 68.8±41.0ab 2.5±0.8ab 2.0±0.7ab 1.9±0.6ab 10.8±5.4b 
         LFRS 210.9±19.5 41.6±4.9a 42.2±11.3ab 294.8±26.4a 2.5±0.4 3.8±0.5 4.9±.6a 11.2±1.4 
LFF 194.3±30.2 48.3±10.4a 88.3±20.4a 330.9±57.5a 1.9±0.5 3.3±0.7 5.6±1.2ab 10.9±2.3 
HFRS 129.4±12.9 20.7±2.9b 20.2±1.8b 170.2±15.8b 2.7±0.4 3.3±0.5 2.6±0.2b 8.6±1.0 
HFF 185.4±32.0 27.6±5.8ab 69.6±18.8a 282.6±57.1a 1.3±0.3 2.0±0.4 2.5±0.6ab 5.7±1.1 
 
 
Table 7:  Cecal short-chain fatty acid profiles after 12 weeks of fiber supplementation. 
 
Mice were placed on a high fat (HF) or a low fat (LF) diet containing either 10% pectin (P), 10% 
cellulose, 10% resistant starch (RS), or 10% fructooligosaccharides (F) for 12 wk.   Different 
letters indicate significant differences among treatments. (n=8, P≤0.05) Values are presented as 






Figure 15:  High fat pectin-fed animals have a greater fecal lipid and fecal energy content then 
cellulose-fed animals 
 
Mice were placed on a high fat (HF) or a low fat (LF) diet containing either 10% pectin (P), 10% 
cellulose (C), 10% fructooligosaccharides (F), or 10% resistant starch (RS).  After 10 wk of 
feeding, mice were placed in metabolic cages and feces were collected for 7 d.  % acid 
hydrolyzed fat (AH) and total energy was measured in fecal samples (n=6, P≤0.001). A) % AH 
fat in fecal samples from P- and C-fed mice.  B) % AH fat in fecal samples from F- and RS-fed 
mice.  C) Fecal energy content in P- and C-fed mice.  Different letters indicate significant 











 Weight (g) 
Visceral fat 





LFP 25.3±0.8a 0.1±0.0a 1.2±0.1a 0.2±0.0a 0.6±0.0a 51.3±1.8a 
LFC 27.0±0.8ab 1.2±0.1a 1.1±0.1a 0.1±0.0b 0.3±0.1ab 38.9±0.8b 
HFP 31.4±1.3b 2.0±0.4ab 1.1±0.0a 0.2±0.0a 0.5±0.0ab 44.0±1.1b 




Table 8:  Pectin reduces adiposity, reduces liver weight, and has a trophic effect on the intestine 
 
 
Mice were placed on a high fat (HF) or a low fat (LF) diet containing either 10% pectin (P) or 
10% cellulose.   After 12 wk of feeding, mice were sacrificed and organs were harvested. 
Different letters indicate significant differences among treatments (n=8, P≤0.05). Values are 







1. Anderson, J. W., P. Baird, R. H. Davis, Jr. S. Ferreri, M. Knudtson, A. Koraym, V. Waters, 
and C. L. Williams. 2009. Health benefits of dietary fiber. Nutr. Rev. 67: 188-205.  
2. Choi, J. S., H. Kim, M. H. Jung, S. Hong, and J. Song. 2010. Consumption of barley beta-
glucan ameliorates fatty liver and insulin resistance in mice fed a high-fat diet. Mol. Nutr. Food 
Res. 54: 1004-1013.  
3. Ushida, K., H. Hatanaka, R. Inoue, T. Tsukahara, and G. Phillips. 2011. Effect of long term 
ingestion of gum arabic on the adipose tissues of female mice. Food Hydrocolloids 25: 1344-
1349.  
4. Lattimer, J. and M. Haub. 2010. Effects of dietary fiber and its components on metabolic 
health. Nutrients 2: 1266-1267.  
5. Landin, K., G. Holm, L. Tengborn, and U. Smith. 1992. Guar gum improves insulin 
sensitivity, blood lipids, blood pressure, and fibrinolysis in healthy men. Am. J. Clin. Nutr. 56: 
1061-1065.  
6. Behall, K. M., D. J. Scholfield, J. G. Hallfrisch, and H. G. Liljeberg-Elmstahl. 2006. 
Consumption of both resistant starch and beta-glucan improves postprandial plasma glucose and 
insulin in women. Diabetes Care 29: 976-981.  
7. Sola, R., E. Bruckert, R. M. Valls, S. Narejos, X. Luque, M. Castro-Cabezas, G. Domenech, F. 
Torres, M. Heras, X. Farres, J. V. Vaquer, J. M. Martinez, M. C. Almaraz, and A. Anguera. 
2010. Soluble fibre (Plantago ovata husk) reduces plasma low-density lipoprotein (LDL) 
cholesterol, triglycerides, insulin, oxidized LDL and systolic blood pressure in 




8. Salas-Salvadó, J., X. Farrésa, X. Luquea, S. Narejosa, M. B. Borrella J., A. Angueraa, F. 
Torresa, M. Bullóa, and R. Balanzaa. 2008. Effect of two doses of a mixture of soluble fibres on 
body weight and metabolic variables in overweight or obese patients: a randomised trial. Br J 
Nutr 99: 1380.  
9. Du, H., A. D. L. van der, H. C. Boshuizen, N. G. Forouhi, N. J. Wareham, J. Halkjaer, A. 
Tjonneland, K. Overvad, M. U. Jakobsen, H. Boeing, B. Buijsse, G. Masala, D. Palli, T. I. 
Sorensen, W. H. Saris, and E. J. Feskens. 2010. Dietary fiber and subsequent changes in body 
weight and waist circumference in European men and women. Am. J. Clin. Nutr. 91: 329-336.  
10. Campagnolo, P. D., M. R. Vitolo, C. M. Gama, and A. T. Stein. 2008. Prevalence of 
overweight and associated factors in southern Brazilian adolescents. Public Health 122: 509-515.  
11. Liu, S., W. C. Willett, J. E. Manson, F. B. Hu, B. Rosner, and G. Colditz. 2003. Relation 
between changes in intakes of dietary fiber and grain products and changes in weight and 
development of obesity among middle-aged women. Am. J. Clin. Nutr. 78: 920-927.  
12. Tucker, L. A. and K. S. Thomas. 2009. Increasing total fiber intake reduces risk of weight 
and fat gains in women. J. Nutr. 139: 576-581.  
13. Reimer, R. A., G. J. Grover, L. Koetzner, R. J. Gahler, M. R. Lyon, and S. Wood. 2011. The 
soluble fiber complex PolyGlycopleX lowers serum triglycerides and reduces hepatic steatosis in 
high-sucrose-fed rats. Nutr. Res. 31: 296-301.  
14. Jimenez-Escrig, A., M. D. Tenorio, I. Espinosa-Martos, and P. Ruperez. 2008. Health-
promoting effects of a dietary fiber concentrate from the soybean byproduct okara in rats. J. 
Agric. Food Chem. 56: 7495-7501.  
15. Artiss, J. D., K. Brogan, M. Brucal, M. Moghaddam, and K. L. Jen. 2006. The effects of a 





16. Bartley, G. E., W. Yokoyama, S. A. Young, W. H. Anderson, S. C. Hung, D. R. Albers, M. 
L. Langhorst, and H. Kim. 2010. Hypocholesterolemic effects of hydroxypropyl methylcellulose 
are mediated by altered gene expression in hepatic bile and cholesterol pathways of male 
hamsters. J. Nutr. 140: 1255-1260.  
17. Birketvedt, G. S., M. Shimshi, T. Erling, and J. Florholmen. 2005. Experiences with three 
different fiber supplements in weight reduction. Med. Sci. Monit. 11: PI5-8.  
18. Mhurchu, C. N., S. D. Poppitt, A. T. McGill, F. E. Leahy, D. A. Bennett, R. B. Lin, D. 
Ormrod, L. Ward, C. Strik, and A. Rodgers. 2004. The effect of the dietary supplement, chitosan, 
on body weight: a randomized controlled trial in 250 overweight and obese adults. Int. J. Obes. 
Relat. Metab. Disord. 28: 1149-1156.  
19. Papathanasopoulos, A. and M. Camilleri. 2010. Dietary fiber supplements: effects in obesity 
and metabolic syndrome and relationship to gastrointestinal functions. Gastroenterology 138: 
65-72.e1-2.  
20. Sood, N., W. L. Baker, and C. I. Coleman. 2008. Effect of glucomannan on plasma lipid and 
glucose concentrations, body weight, and blood pressure: systematic review and meta-analysis. 
Am. J. Clin. Nutr. 88: 1167-1175.  
21. Wang, Z. Q., A. R. Zuberi, X. H. Zhang, J. Macgowan, J. Qin, X. Ye, L. Son, Q. Wu, K. 
Lian, and W. T. Cefalu. 2007. Effects of dietary fibers on weight gain, carbohydrate metabolism, 
and gastric ghrelin gene expression in mice fed a high-fat diet. Metabolism 56: 1635-1642.  
22. Meyer, K., L. Kushi, D. Jacobs, J. Slavin, T. Sellers, and A. Folsom. 2000. Carbohydrates, 
dietary fiber, and incident type 2 diabetes in older women. Am J Clin Nutr 71: 921-925.  
23. Raninen, K., J. Lappi, H. Mykkanen, and K. Poutanen. 2011. Dietary fiber type reflects 





24. Lairon, D., B. Play, and D. Jourdheuil-Rahmani. 2007. Digestible and indigestible 
carbohydrates: interactions with postprandial lipid metabolism. J. Nutr. Biochem. 18: 217-227.  
25. Anderson, J. W. and W. J. Chen. 1979. Plant fiber. Carbohydrate and lipid metabolism. Am. 
J. Clin. Nutr. 32: 346-363.  
26. Delzenne, N. M. and N. N. Kok. 1999. Biochemical basis of oligofructose-induced 
hypolipidemia in animal models. J. Nutr. 129: 1467S-70S.  
27. Delzenne, N. M. 2003. Oligosaccharides: state of the art. Proc. Nutr. Soc. 62: 177-182.  
28. Erwin, E. S., G. J. Marco, and E. M. Emery. 1961. Volatile fatty acid analyses of blood and 
rumen fluid by gas chromatography. J. Dairy Sci. 44: 1446-1456.  
29. Association of Official Analytical Chemists. 1984. Official Methods of Analysis. 14
th
 ed. 
AOAC, Washington, DC.  
30. American Association of Cereal Chemists. 1983. Approved Methods. 8
th
 ed.AACC, St. Paul, 
MN.  
31. Hove, E. L. and S. King. 1979. Effects of pectin and cellulose on growth, feed efficiency, and 
protein utilization, and their contribution to energy requirement and cecal VFA in rats. J. Nutr. 
109: 1274-1278.  
32. Hillman, L., S. Peters, A. Fisher, and E. W. Pomare. 1983. Differing effects of pectin, 
cellulose and lignin on stool pH, transit time and weight. Br. J. Nutr. 50: 189-195.  
33. Klosterbuer, A., Z. F. Roughead, and J. Slavin. 2011. Benefits of dietary fiber in clinical 
nutrition. Nutr. Clin. Pract. 26: 625-635.  
34. Lin, T. M., K. S. Kim, E. Karvinen, and A. C. Ivy. 1957. Effect of dietary pectin, protopectin 
and gum arabic on cholesterol excretion in rats. Am. J. Physiol. 188: 66-70.  
35. Kay, R. M. and A. S. Truswell. 1977. Effect of citrus pectin on blood lipids and fecal steroid 
excretion in man. Am. J. Clin. Nutr. 30: 171-175.  
89 
 
36. Garcia-Diez, F., V. Garcia-Mediavilla, J. E. Bayon, and J. Gonzalez-Gallego. 1996. Pectin 
feeding influences fecal bile acid excretion, hepatic bile acid, and cholesterol synthesis and 
serum cholesterol in rats. J. Nutr. 126: 1766-1771.  
37. Falk, J. D. and J. J. Nagyvary. 1982. Exploratory studies of lipid-pectin interactions. J. Nutr. 
112: 182-188.  
38. Somm, E., P. Cettour-Rose, C. Asensio, A. Charollais, M. Klein, C. Theander-Carrillo, C. E. 
Juge-Aubry, J. M. Dayer, M. J. Nicklin, P. Meda, F. Rohner-Jeanrenaud, and C. A. Meier. 2006. 
Interleukin-1 receptor antagonist is up-regulated during diet-induced obesity and regulates 
insulin sensitivity in rodents. Diabetologia 49: 387-393.  
39. Garcia, M. C., I. Wernstedt, A. Berndtsson, M. Enge, M. Bell, O. Hultgren, M. Horn, B. 
Ahren, S. Enerback, C. Ohlsson, V. Wallenius, and J. O. Jansson. 2006. Mature-onset obesity in 
interleukin-1 receptor I knockout mice. Diabetes 55: 1205-1213.  
40. Oh-I, S., J. P. Thaler, K. Ogimoto, B. E. Wisse, G. J. Morton, and M. W. Schwartz. 2010. 
Central administration of interleukin-4 exacerbates hypothalamic inflammation and weight gain 
during high-fat feeding. Am. J. Physiol. Endocrinol. Metab. 299: E47-53.  
41. Takeda, K., T. Kaisho, and S. Akira. 2003. Toll-like receptors.  Annu. Rev. Immunol. 21: 
335-346.  
42. Strohacker, K., R. J. Simpson, K. C. Carpenter, W. L. Breslin, and B. K. McFarlin. 2010. 
Longitudinal, diet-induced weight gain is associated with increased blood monocytes and 
reduced TLR4 expression. Int. J.  Exer. Sci. 3:145-149.  
43. Johnson, G. B., B. L. Riggs, and J. L. Platt. 2004. A genetic basis for the "Adonis" phenotype 
of low adiposity and strong bones. FASEB J. 18: 1282-1284.  
44. Himes, R. W. and C. W. Smith. 2010. TLR2 is critical for diet-induced metabolic syndrome 
in a murine model. FASEB J. 24: 731-739.  
90 
 
45. Kleinridders, A., D. Schenten, A. C. Konner, B. F. Belgardt, J. Mauer, T. Okamura, F. T. 
Wunderlich, R. Medzhitov, and J. C. Bruning. 2009. MyD88 signaling in the CNS is required for 
development of fatty acid-induced leptin resistance and diet-induced obesity. Cell. Metab. 10: 
249-259.  
46. Kimmel, S. E., K. E. Michel, R. S. Hess, and C. R. Ward. 2000. Effects of insoluble and 
soluble dietary fiber on glycemic control in dogs with naturally occurring insulin-dependent 
diabetes mellitus. J. Am. Vet. Med. Assoc. 216: 1076-1081.  
47. Li, J., T. Kaneko, L. Q. Qin, J. Wang, Y. Wang, and A. Sato. 2003. Long-term effects of high 
dietary fiber intake on glucose tolerance and lipid metabolism in GK rats: comparison among 
barley, rice, and cornstarch. Metabolism 52: 1206-1210.  
48. Tamura, M., Y. Ohnishi, T. Kotani, and N. Gato. 2011. Effects of new dietary fiber from 
Japanese apricot (Prunus mume Sieb. et Zucc.) on gut function and intestinal microflora in adult 
mice. Int. J. Mol. Sci. 12: 2088-2099.  
49. Villanueva, M., W. Yokoyama, Y. Hong, G. Barttley, and P. Ruperex. 2010. Effect of high-
fat diets supplemented with okara soybean by-product on lipid profiles of plasma, liver and 
feaces in Syrian hamsters. Food Chemistry 124: 72-78.  
50. Jenkins, D. J., T. M. Wolever, A. R. Leeds, M. A. Gassull, P. Haisman, J. Dilawari, D. V. 
Goff, G. L. Metz, and K. G. Alberti. 1978. Dietary fibres, fibre analogues, and glucose tolerance: 
importance of viscosity. Br. Med. J. 1: 1392-1394.  
51. Tahri, K., J. P. Grill, and F. Schneider. 1996. Bifidobacteria strain behavior toward 
cholesterol: co-precipitation with bile salts and assimilation. Curr. Microbiol. 33: 187-193.  
52. Spiller, G. A., M. C. Chernoff, R. A. Hill, J. E. Gates, J. J. Nassar, and E. A. Shipley. 1980. 
Effect of purified cellulose, pectin, and a low-residue diet on fecal volatile fatty acids, transit 
time, and fecal weight in humans. Am. J. Clin. Nutr. 33: 754-759.  
91 
 
53. Fukunaga, T., M. Sasaki, Y. Araki, T. Okamoto, T. Yasuoka, T. Tsujikawa, Y. Fujiyama, and 
T. Bamba. 2003. Effects of the soluble fibre pectin on intestinal cell proliferation, fecal short 
chain fatty acid production and microbial population. Digestion 67: 42-49.  
54. Backhed, F., H. Ding, T. Wang, L. V. Hooper, G. Y. Koh, A. Nagy, C. F. Semenkovich, and 
J. I. Gordon. 2004. The gut microbiota as an environmental factor that regulates fat storage. 
Proc. Natl. Acad. Sci. 101: 15718-15723.  
55. Demigne, C., C. Morand, M. A. Levrat, C. Besson, C. Moundras, and C. Remesy. 1995. 
Effect of propionate on fatty acid and cholesterol synthesis and on acetate metabolism in isolated 
rat hepatocytes. Br. J. Nutr. 74: 209-219.  
56. Hu, G. X., G. R. Chen, H. Xu, R. S. Ge, and J. Lin. 2010. Activation of the AMP activated 
protein kinase by short-chain fatty acids is the main mechanism underlying the beneficial effect 
of a high fiber diet on the metabolic syndrome. Med. Hypotheses 74: 123-126.  
57. Zambell, K. L., M. D. Fitch, and S. E. Fleming. 2003. Acetate and butyrate are the major 
substrates for de novo lipogenesis in rat colonic epithelial cells. J. Nutr. 133: 3509-3515.  
58. Klaver, F. A. and R. van der Meer. 1993. The assumed assimilation of cholesterol by 
Lactobacilli and Bifidobacterium bifidum is due to their bile salt-deconjugating activity. Appl. 
Environ. Microbiol. 59: 1120-1124.  
59. Noriega, L., I. Cuevas, A. Margolles, and C. G. de los Reyes-Gavilán. 2006. Deconjugation 
and bile salts hydrolase activity by Bifidobacterium strains with acquired resistance to bile. Int. 
Dairy J.  6: 850-855.  
60. Massimino, S. P., M. I. McBurney, C. J. Field, A. B. Thomson, M. Keelan, M. G. Hayek, and 
G. D. Sunvold. 1998. Fermentable dietary fiber increases GLP-1 secretion and improves glucose 
homeostasis despite increased intestinal glucose transport capacity in healthy dogs. J. Nutr. 128: 
1786-1793.  
61. Sigleo, S., M. J. Jackson, and G. V. Vahouny. 1984. Effects of dietary fiber constituents on 
intestinal morphology and nutrient transport. Am. J. Physiol. 246: G34-39.  
92 
 
62. Brown, R. C., J. Kelleher, and M. S. Losowsky. 1979. The effect of pectin on the structure 
and function of the rat small intestine. Br. J. Nutr. 42: 357-365.  
63. Pirman, T., M. C. Ribeyre, L. Mosoni, D. Remond, M. Vrecl, J. Salobir, and P. Patureau 
Mirand. 2007. Dietary pectin stimulates protein metabolism in the digestive tract. Nutrition 23: 
69-75.  
64. Langhout, D. J., J. B. Schutte, P. Van Leeuwen, J. Wiebenga, and S. Tamminga. 1999. Effect 
of dietary high- and low-methylated citrus pectin on the activity of the ileal microflora and 
morphology of the small intestinal wall of broiler chicks. Br. Poult. Sci. 40: 340-347.  
65. Parnell, J. A. and R. A. Reimer. 2010. Effect of prebiotic fibre supplementation on hepatic 




























Summary and Discussion 
 
The main findings from this study support increasing epidemiologic reports of negative 
associations between obesity and cognition.  A high fat diet (HFD) induced anxiety-like 
behavior, increased reward-seeking, and decreased both spatial and non-spatial memory after 
only 1 week of feeding.  HFD-induced memory deficit was reversed by ceasing HFD feeding, 
indicating a transient effect of the diet. Additionally, short-term HFD feeding disrupted brain-
derived neurotrophic growth factor (BDNF) and nerve growth factor (NGF), growth factors 
involved in neuronal plasticity and the dopaminergic pathway in the cortex.   Administration of a 
dopamine transport inhibitor, methylphendidate, restored non-spatial memory, while 
administration of anti-depressants did not. More studies are being published suggesting a 
common mechanism between obesity and attention deficit disorder.  Both obesity and attention 
deficit disorder may involve alterations inthe dopamine reward system. Further research is 
needed to explore the role of the HFD in these conditions.  BDNF is closely related to the 
dopamenergic pathway and dopamenergic functions.  Dopamine agonists have been shown to 
regulate expression of BDNF, indicating dopamine is a regulator of BDNF in the prefrontal 
cortex.  In this study, we have demonstrated a decrease in BDNF expression in the cortex of 
HFD fed mice after 1 week of feeding suggesting dopamine levels may also be altered, as a 
decreased in dopamine would lead to a decrease in BDNF expression.  Dopamine levels in the 
cortex are thought to be related to cognition, while dopamine levels in the striatum are thought to 
be related to motivation.   To confirm the role of dopamine in memory deficit and reward-
seeking behavior noted in this study, the amount of dopamine in the pre-frontal cortex and 
striatum in HFD- and LFD-fed mice could be measured using HPLC methods.   Decreases in 
dopamine in the cortex of HFD-fed mice compared to LFD-fed mice would lend evidence to the 
hypothesis that decreased dopamine is a contributing factor to the non-spatial and spatial 
memory deficit seen in HFD-fed mice.  Altered expression of dopamine receptor 2 (DRD2) and 
dopamine receptor 4 (DRD4) in striatum and prefrontal cortex, respectively, have been 
associated with alerted dopamine transport activity as well as psychiatric disorders such as 
ADHD.  DRD2 has been associated with motivational activity, while deficiency of DRD4 had 
been linked to impaired memory.  Expression of dopamine receptor 1 (DRD1) is especially high 
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in the prefrontal cortex and is the most abundant dopamine receptor found in this region.  
Stimulation of DRD1 and DRD2 receptors with a dopamine agonist in vitro increased NGF.  In 
addition, DRD1 receptors have been found to be involved in object recognition.  To determine 
whether a HFD alters the expression of dopamine receptors in the cortex and striatum, DRD1, 
DRD2, and DRD4 mRNA expression could be measured in the cortex and striatum of HFD- and 
LFD-fed mice after 1 and 3 weeks of feeding.  Alternately, dopamine receptor knock-out mice 
could be used. 
  
Additionally, this study found that pectin is protective against diet-induced obesity in a 
dose-dependent matter. Pectin also was found to be protective against hyperglycemia.  Resistant 
starch and fructooligosaccharides, soluble, fermentable fibers, were not protective against weight 
gain.  In fact, they shared a similar weight gain pattern to cellulose, a non-digestible, non-
fermentable fiber.  Interestingly, pectin was not protective against weight gain in TLR4-/- and 
TLR2-/- mice, suggesting the protective effect of pectin, may involve the TLR signaling 
pathway.  In wild-type mice, pectin appeared to protect against weight gain my increasing fecal 
lipid excretion.  To further explore the mechanism by which pectin protects against weight gain, 
fecal lipid excretion could be examined in TLR4-/- mice.   TLR4-/- mice are to some extent, 
immune to weight gain.  It is possible that TLR4-/- mice have increased fecal lipid excretion 
similar to pectin-fed HFD mice.  The effect of pectin on weight reduction could also be the result 
of communication through fatty acid receptors.  To test this hypothesis, fatty acid receptor 
knockout mice could be fed the DF high fat diets to determine if pectin would still be protective 
if the fatty acid receptors were not functional.    
  
These studies demonstrated the detrimental effect of a HFD on memory and cognition and the 
protective effect of pectin on diabesity.  An interesting study would be to test memory and 
cognition in juvenile mice receiving a HFD supplemented with pectin to determine if pectin is 
also protective against HFD-induced memory deficit.   
 
 
 
  
